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SUMMARY 
 
Chronic myeloid leukaemia (CML) is a disorder of the haematopoietic stem cell 
(HSC)  characterised  by  the  presence  of  a  characteristic  chromosomal 
translocation which forms the Philadelphia chromosome. The disease is caused by 
BCR-ABL, a constitutively active tyrosine kinase and the  protein  product of the 
oncogene BCR-ABL which forms as a result of the chromosomal translocation. 
 
The  current  recommended  treatment  for  the  majority  of  patients  with  chronic 
phase (CP) CML is the tyrosine kinase inhibitor (TKI) imatinib mesylate (IM). There 
is accumulating evidence that the majority of patients respond to this drug and 
achieve  the  therapeutic  milestone  of  a  complete  cytogenetic  response  (CCyR). 
However TKI induce a state of minimal residual disease (MRD) in the majority with 
BCR-ABL transcripts detectable in peripheral blood (PB). The source of MRD in IM 
treated  patients  is  presumed  to  be  leukaemic  HSC.  These  cells  are  relatively 
insensitive  to  all  TKI.  Furthermore  the  development  of  TKI-resistant  BCR-ABL 
mutations is a cause of primary and secondary treatment failure. In particular the 
T315I BCR-ABL mutation is resistant to all available TKI and there is concern that 
selection pressure may result in this mutation becoming more prevalent. 
 
The  proteasome  is  an  attractive  target  for  cancer  therapy  and  there  has  been 
expansion of the clinical use of bortezomib, to date the only licensed proteasome 
inhibitor (PI). There is published evidence that BCR-ABL expression is associated 
with increased proteasome activity, that primitive CML cells express higher levels 
of BCR-ABL than their more mature progeny and that BCR-ABL+ cell lines are 
susceptible  to  proteasome  inhibition  (1-4).  We  have  extended  this  work  to 
demonstrate that CD34 enriched samples taken at diagnosis from patients with CP 
CML have reduced proliferation and undergo apoptosis with bortezomib exposure. 
This  effect  was  replicated  in  7  different  patient  samples  and  the  drug  was 
consistent in its effect. The antiproliferative and apoptotic effects were associated 
with an accumulation of polyubiquitinated proteins consistent with inhibition of the 
proteasome. Despite these effects, bortezomib did not appear to influence BCR-
ABL  kinase  activity  as  evident  by  pCrkl  detection  by  Western  blot.  The 
concentration required to reduce the viable cell count by 50% (LD50) in CD34+ 
CML cells was comparable to that quoted previously for CML blast crisis (BC) cell 
lines (10-15 and 32nM at 48 hours (h) (1, 3)), purified human multiple myeloma   16 
cells from bone marrow (BM) (2.5-30nM at 48h (5)) and CD34 enriched human 
acute myeloid leukaemia (AML) cells (5-10nM at 7 days (d) (6)). Pharmacokinetic 
and  pharmacodynamic  data  from  treated  patients  would  suggest  that  such 
concentrations are clinically achievable. 
 
We  used  an  established  technique  to  isolate  the  CD34+38-  cells  from  patient 
samples.  This  population  contains  the  primitive  and  quiescent  HSC  which  are 
resistant to current therapies. We demonstrate for the first time that these cells are 
sensitive to the apoptotic effects of bortezomib at comparable concentrations to 
those  achieved  in  vivo.  These  data  are  in  concordance  with  published 
observations of the sensitivity of CD34+38- AML cells to the PI MG132 (7). We 
extended  the  work  to  track  cells  through  division  using  carboxy-fluorescein 
diacetate  succinimidyl
  diester  (CFSE)  staining  and  flow  cytometry.  We 
demonstrate  that  proliferation  of  CD34+  CML  cells  is  significantly  affected  by 
bortezomib exposure  and  at high  concentrations the  few surviving cells remain 
undivided. Recovery calculations were made and at concentrations of bortezomib 
comparable  to  the  LD50  there  is  a  depletion  of  CD34+  cells  from  all  stages  of 
division  including  the  undivided  state.  This  contrasts  with  dasatinib  exposure, 
which may result in the accumulation of undivided cells. 
 
Clinical trials with bortezomib have shown that reversible haematological toxicity 
(in particular severe thrombocytopaenia) is very common. We show that normal 
CD34+38- cells are susceptible to the apoptotic effects of bortezomib with LD50 
values only slightly higher than those of the CML HSC. We could find no published 
data of the effects of bortezomib in this specific cell population. Other groups have 
used, as a control population, non-malignant CD34+ enriched cells (LD50 11.3nM 
by  assays  of  colony  formation  and  <20nM  by  proliferation  assays  (6,  8))  and 
lymphocytes from PB (~5% apoptosis with 50nM by annexin-V staining (9)). The 
toxicity we demonstrate is concerning, however the reversible nature of the severe 
cytopaenias seen in patients may reflect an improved recovery of this population 
relative to malignant cells. It is noted that in Phase I dose escalation studies using 
more intensive regimes, the dose-limiting toxicity was haematological (10).  
 
An established technique to ameliorate toxicity  of chemotherapy is to use drug 
combinations.  We  speculated  that  TKI  may  provide  additional  benefits  to 
bortezomib treatment in view of the presence of residual BCR-ABL kinase activity   17 
in PI treated cells. We demonstrate that bortezomib and dasatinib are synergistic 
in inducing cell death using concentrations of both drugs that may be achieved in 
vivo.  
 
We have also shown that bortezomib consistently induces apoptosis in cell lines 
expressing  BCR-ABL  mutations  including  T315I.  This  is  associated  with  a 
reduction in chymotrypsin-like (CT-L) enzyme activity consistent with bortezomib 
effect. Interestingly we show for the first time that the proteasome subunit activity 
may vary amongst different BCR-ABL mutations and this is not thought to be due 
to different BCR-ABL protein levels.  
 
In conclusion bortezomib is antiproliferative and induces apoptosis in CML CD34+ 
cells  including  the  CD34+38-  fraction,  believed  to  be  the  source  of  residual 
disease in TKI treated patients. Potential toxicities associated with this drug may 
be bypassed by synergistic interactions with dasatinib. Bortezomib is also effective 
in the presence of TKI resistant BCR-ABL mutations. With these two key findings 
we  believe that PI  should play  a future role in  the treatment  of patients failing 
current therapies. 
   18 
1 INTRODUCTION 
 
1.1 Classification 
CML  is  classified  by  the  World  Health  Organisation  as  a  myeloproliferative 
disorder,  one  member  of  a  group  of  conditions  including  essential 
thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis. The 
myeloproliferative  diseases  are  clonal  disorders  of  the  HSC  characterised  by 
abnormal  myeloid  (i.e.  granulocyte,  erythroid  and  megakaryocytic)  proliferation. 
CML  (also  termed  chronic  myelogenous  or  granulocytic  leukaemia)  has  a 
characteristic molecular biology and is now more appropriately considered as a 
distinct entity. 
 
1.2 Epidemiology 
CML has an estimated incidence of 1-2 new cases per 100000 population per year 
(y) (11). Figures from Scotland (1980-2005) are in concordance with this, with an 
average  of  60  new  cases/y  from  a  population  of  approximately  5  million.  The 
incidence has changed little in Scotland over the decade 1994-2004.  The median 
age affected is between 65y and 69y with a slight male predominance (cancer 
statistics  accessed  in  January  2009  from  the  National  Statistics  section  of  the 
Information  Services  Division  (ISD)  Scotland,  www.isdscotland.org  and  general 
population  statistics  from  the  General  Register  Office  for  Scotland,  www.gro-
scotland.gov.uk). 
 
1.3 Clinical Manifestations 
CML evolves through 3 clinical phases.  The CP is characterised by leucocytosis 
and  hepatosplenomegaly  developing  as  a  consequence  of  increased 
granulopoeisis and leukaemic infiltration.  At diagnosis the majority of patients are 
in CP and are asymptomatic. The disease will then progress either directly to BC 
or through an intermediate accelerated phase (AP).  AP is characterised by an 
increased number of primitive precursors in BM or PB. BC occurs when there is a 
failure of maturation of the malignant precursors, often accompanied by additional 
cytogenetic  abnormalities  and  resulting  in  a  disease  resembling  AML  or  acute 
lymphoblastic  leukaemia  (ALL).    There  have  been  significant  advances  in  the 
treatment  of  CP  disease  and  progression  to  advanced  stage  is  seen  less 
frequently. However, when it occurs the prognosis is poor and the median survival 
measured in months (m) (11).     19 
1.4 Pathogenesis 
CML arises as a consequence of a rare mutational event resulting in a reciprocal 
translocation between the long arms of chromosomes 9 and 22. The shortened 
chromosome  22  formed  by  this  translocation  is  the  Philadelphia  chromosome 
(Ph+), named after the city in which it was discovered. The translocation creates 
the chimeric oncogene BCR-ABL with the protein product BCR-ABL, a tyrosine 
kinase with constitutive activity. BCR-ABL is responsible for the pathogenesis of 
CML as demonstrated by the transforming ability of BCR-ABL expression in cell 
lines and mice (12, 13).  This oncoprotein is therefore the focus for investigations 
into the pathogenesis of CML and has provided a tangible target for therapy. 
 
1.5 BCR-ABL and the malignant phenotype 
BCR-ABL confers a survival advantage on cells by influencing signalling pathways 
which  control  proliferation  and  apoptosis.  It  may  be  the  advantage  is  relatively 
subtle: BCR-ABL is detectable, transiently it is presumed, in a “normal” population 
(14, 15); and exposure to known triggers of CML, such as ionising radiation, have 
a disease latency of years (16). An outline of the signalling pathways affected by 
BCR-ABL provides insight into the mechanism by which the malignant phenotype 
may be established. 
 
1.5.1 Intracellular signalling pathways 
Enzyme-linked receptors provide a mechanism for cell signalling and play a role in 
proliferation,  differentiation,  apoptosis  and  migration. Of the different  classes  of 
enzyme-linked  receptors,  the  most  common  have  tyrosine  kinase  function 
(receptor tyrosine kinase, RTK) and include the RAS and phosphatidylinositol 3-
kinase (PI3K) pathways (Figure 1.1). Others are associated with proteins which 
have tyrosine kinase activity and include the Janus kinase (JAK) pathways (Figure 
1.2).  
 
1.5.1.1. RAS and PI3K pathways 
In  outline,  RTK  binding  results  in  autophosphorylation  and  so  provides 
phosphotyrosine docking sites for intracellular proteins containing SRC-homology-
2 (SH2) domains. Once bound, SH2-containing proteins may interact with other 
tyrosine  phosphorylated  proteins. This interaction may take  place via  additional 
binding domains, such as SH3 domains, on the signalling molecule.    20 
RAS  is  a  guanosine  triphosphate  (GTP)-binding  protein  associated  with  RTK 
(Figure 1.1). Through activation of RAS and downstream serine-threonine kinases 
the activity of gene regulatory proteins are influenced - including those responsible 
for cell proliferation. It has been demonstrated previously that BCR-ABL interacts 
directly  with  growth  factor  receptor  bound-2  (GRB-2)  and  activates  the  RAS 
pathway  (17).  Furthermore,  inhibition  of  tyrosine  kinase  activity  abrogates  the 
activation of RAS (18). Consistent with this, BCR-ABL+ cell lines have detectable 
levels of RAF activity and colony growth of CML cells appears to depend on this 
(19).  
 
A  further  relevant  and  important  signalling  pathway  activated  through  RTK 
involves  PI3K  activation  (Figure  1.1).  Through  PI3K  there  is  promotion  of  cell 
growth and survival through a pathway involving AKT (a serine-threonine kinase) 
with downstream targets which include mammalian target of rapamycin (mTOR). 
BCR-ABL interacts with and promotes activity of PI3K. Inhibition of PI3K in BCR-
ABL+  cells  will  inhibit  growth  (20).  AKT  activity  is  also  essential  in  BCR-ABL 
mediated leukaemogenesis seen in vitro as colony growth and in vivo in mouse 
transplantation models (21).   21 
 
 
Figure 1.1. RAS activation. RAS exists in active (GTP-bound – activated by GEF) 
and  inactive (GDP-bound  –  inactivated by  GAP).  RAS is linked  to the RTK  by 
adaptor proteins including GRB-2. GRB-2 contains an SH2 domain (so binding to 
the RTK) and two SH3 domains. Through the SH3 domains GRB-2 is associated 
with SOS proteins which function as a GEF (so activating RAS). Activated RAS 
recruits  and  activates  MAPKKK  (=RAF)  which  then  activates  MAPKK  (=MEK) 
activating  MAPK  (=ERK).  ERK  then  influences  the  activity  of  gene  regulatory 
proteins and through this cellular proliferation. PI3K activation. PI3K catalyses the 
generation of PIP2 and PIP3. These phospholipids contain docking sites for PH-
domain containing signalling proteins, enabling them to come in close proximity 
and  so  interact.  An  important  example  is  PIP3  dependent  activation  of  AKT,  a 
process  requiring  phosphorylation  of  AKT  by  PDK1.  Once  activated  AKT 
phosphorylates many target proteins including mTOR, which serve to promote cell 
growth and survival. 
Abbreviations in figure and legend– RAS pathway Guanosine triphosphate (GTP), 
Guanine  nucleotide  exchange  factors  (GEF),  guanosine  diphosphate  (GDP), 
GTPase-activating proteins (GAP), receptor tyrosine kinase (RTK), growth factor 
receptor  bound-2  (GRB-2),  SRC-homology-3  (SH3),  Son  of  Sevenless  (SOS), 
mitogen activated protein kinase (MAPK), MAPK kinase (MAPKK), MAPKK kinase 
(MAPKKK), MAPK/ERK kinase (MEK),  extracellular signal-related kinase (ERK) 
PI3K  pathway  Phosphatidylinositol  3-kinase  (PI3K),  phosphatidylinositol  (3,4) 
diphosphate  (PI(3,4)P2),  phosphatidylinositol  (3,4)  triphosphate  (PI(3,4,5)P3), 
pleckstrin homology (PH), 3-phosphoinositide-dependent protein kinase 1 (PDK1), 
mammalian target of rapamycin (mTOR). 
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1.5.1.2. JAK pathway 
The  Janus  kinase  (JAK)  family  are  cytoplasmic  tyrosine  kinases  activated 
following cytokine receptor binding (Figure 1.2). This activation proceeds through 
signal transducers and activators of transcription (STAT) proteins which directly 
regulate  gene  activity  promoting  expression  of  anti-apoptotic  factors  (including 
BCL-XL). STAT overexpression is seen in cancers including CML and it has been 
shown in BCR-ABL+ cells that STAT1/3/5 are phosphorylated and constitutively 
active (22-24). This activity may be abrogated by TKI (25, 26). 
 
 
Figure 1.2 Activation of JAK results in activation of STAT proteins which directly 
regulate gene activity. STAT proteins contain an SH2 domain and may also be 
activated independently of JAK. 
Abbreviations - Janus family kinase (JAK),  signal transducers and activators of 
transcription (STAT), proteins. 
 
1.6 The haematopoietic stem cell in CML 
 
1.6.1 The leukaemic stem cell 
The  normal  HSC  performs  characteristic  stem  cell  functions  of  self-renewal, 
allowing  perpetuation  of  haemopoiesis  and  the  production  of  differentiated 
progeny, initially as lineage-restricted progenitors through to mature blood cells. 
These functions are regulated by soluble cytokines and interactions between cells 
and stroma. The term “HSC” describes a relatively heterogenous group of cells 
with varying self-renewal capacity and propensity to generate different lineages. In 
CML there is a population of leukaemic HSC characterised by the presence of the 
Philadelphia  chromosome  and  BCR-ABL  oncogene  (Ph+HSC).  Consistent  with 
Ph+HSC precursors, BCR-ABL containing cells of all lineages (excluding mature T 
cells) are seen by different techniques, including: conventional cytogenetics (27, 
28); glucose-6-phosphate dehydrogenase clonality (29); and fluorescence in-situ 
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Anti-apoptotic factors   23 
hybridisation analysis (FISH) following fluorescence activated cell sorting (FACS) 
(30). The clinical consequence of the HSC basis is reflected in the manifestation of 
a broad range of disease subtypes associated with progression to BC CML.   
 
The majority of normal HSC are quiescent, stabilised in cell cycle resting stage 
G0, with infrequent cell cycles every 1-3m (31, 32). The turnover of the Ph+HSC is 
deregulated with the majority of cells in cycle at any given time. These cells show 
autocrine IL-3 and granulocyte-colony stimulating factor (G-CSF) production and 
so may proliferate in the absence of exogenous growth factors (33). Despite this, it 
is estimated that approximately 0.5% of Ph+HSC remain quiescent and represent 
a more primitive Ph+HSC sub-population. These quiescent cells are capable of 
generating  BCR-ABL+  progeny  in  immunocompromised  (non-obese  diabetic, 
severe combined immunodeficiency, NOD/SCID) mice, indicating that in vivo the 
quiescent state is reversible (34). In common with CML, both AML and ALL are 
thought  to  have  a  leukaemic  HSC  basis  with  cells  identified  capable  of 
reconstituting  disease  following  engraftment  in  NOD/SCID  mice  (35,  36).  The 
diseased HSC is a key target for therapy - these cells may act as a reservoir of 
disease and through quiescence, self-renewal and increased proliferative potential 
be  resistant  to  conventional  therapy  and  remain  capable  of  reconstituting  the 
disease state. 
 
Isolation  of  HSC  relies  on  defining  particular  morphological  and  molecular 
characteristics. A combination of functional assays - to exploit HSC self-renewal 
and multi-lineage differentiation - and FACS have identified particular molecular 
characteristics  of  HSC  in  the  normal  and  leukaemic  state  (Table  1.1).  Colony 
formation is a functional assay. By this technique, cells are cultured in conditions 
to encourage proliferation and differentiation. The number of colonies formed will 
correlate to the number of colony-forming units (CFU) and hence indicate HSC 
number  and  function.  A  long  term  culture-initiating  cell  (LTC-IC)  assay  is  a 
modification of this technique. Here a sample of cells containing primitive HSC is 
maintained  for  5-8  weeks  in  culture  on  an  established,  irradiated,  supportive 
stromal  cell  layer.  The  cells  are  then  harvested  and  cultured  in  conditions  to 
encourage  colony  formation.  The  formation  of  colonies  will  correlate  to  the 
persistence of primitive HSC throughout long-term culture. FACS when combined 
with  functional  assays  has  enabled  identification  of  molecular  characteristics 
particular to primitive HSC.    24 
Table 1.1. Characterisation of leukaemia initiating cells 
Cell 
type 
Molecular characterisation  Proof of stem cell 
nature 
Reference 
normal  CD34+38-  Single-sorted cells give 
rise to sequential plated 
colonies 
(37) 
normal  CD34+38-33-  LTC-IC  (38) 
AML  CD34+38-HLA-DR-CD71- 
(most cells capable of LTC-IC 
were CD34+38-) 
LTC-IC 
NOD/SCID mice 
leukaemia initiating cells 
(39) 
AML  CD34+38-  SCID mice leukaemia 
initiating cells 
(35) 
AML  CD34+38-Hoechst 3342-*  CFU 
LTC-IC 
NOD/SCID leukaemia 
initiating cells 
(40) 
CML  CD34+38-  NOD/SCID mice 
leukaemia initiating cells 
(41) 
Normal  cells  are  those  from  healthy  donors.  *Stem  cells  are  believed  to  be 
particularly efficient at effluxing the dyes Hoechst 33342 and Rhodamine (termed 
“side population” due to appearance on FACS). Colony-forming units (CFU) and 
long term culture-initiating cell (LTC-IC) assays. 
 
The selected studies seen in Table 1.1 demonstrate that selection of CD34+38- 
cells  will  contain  cells  with  the  capacity  to  self  renew  and  form  multi-lineage 
colonies and so have key HSC characteristics. Furthermore, a high proportion of 
CD34+38- cells are in G0 and have a high proliferative potential (as measured by 
response  to  in  vitro  stimulation  with  growth  factors)  (42).  This  population  may 
therefore have a role in studies to monitor therapeutic effects on the more primitive 
HSC. 
 
1.6.2 Advanced phase disease and self-renewal capacity 
CP disease is associated with myeloid lineage leucocytosis and this reflects the 
capacity of the Ph+HSC to differentiate to mature progeny. More advanced phases 
of the disease resemble acute leukaemia and are associated with accumulation of 
poorly  differentiated  cells.  This  is  the  consequence  of  a  cumulative  effect  of 
different  genetic  insults  to  the  Ph+HSC.  These  include  BCR-ABL  mediated   25 
deficiencies  in  DNA  repair,  genomic  surveillance,  loss  of  tumour  suppressor 
function and telomere shorting (reviewed (43)). Of interest is recent speculation 
that  progression  to  advanced  stages  may  be  associated  with  the  gain  of  self-
renewal  function  in  granulocyte-macrophage  progenitor  (GMP)  cells.  GMP  are 
differentiated from HSC and would not normally have the capacity for self-renewal. 
However,  a  population  of  GMP  cells  selected  from  BC  CML  by  FACS  were 
capable of initiating leukaemia in mice (44) and BCR-ABL+ mouse GMP cells were 
capable of expanding in vitro (45). In both examples GMP self-renewal capacity 
was  associated  with  activation  of  the  β-catenin,  a  component  of  the  WNT 
signalling pathway. 
 
1.7 Current CML therapy 
 
1.7.1 Imatinib 
The  current  recommended  first  line  therapy  for  patients  with  CP  CML  is  IM 
(Glivec®,  Novartis  Pharma,  Basel,  Switzerland)  (46),  a  rationally  designed  TKI 
which  gained  a  UK  license  in  2001.  IM  underwent  successful  phase  1  dose-
escalation  studies  (47,  48)  and  phase  2  trials  (49)  in  patients  with  CML.  This 
culminated  in  the  phase  3  International  Randomized  study  of  Interferon  and 
STI571 (IRIS) trial. In this untreated, newly-diagnosed patients with CP CML were 
randomised  to  receive  either  IM  400mg  or  interferon-alpha  combined  with  low 
dose  cytosine  arabinoside  (IFNα  +  Ara-C).  The  results  showed  IM  as  superior 
when  considering  haematological  (HR)  and  cytogenetic  responses  (CyR), 
tolerability, or the likelihood of disease progression (50, 51). Table 1.2 outlines 
accepted response criteria and definitions for CML clinical trials. Recent results of 
front line IM therapy for CP CML show complete HR (CHR) in 97% and CCyR in 
82% (best observed responses). Disease progression was low but detectable in 0-
2.8% patients/y (52). Other multi-centre experiences with IM have been published. 
De Lavallade et al. analysed response to IM in 204 patients with newly diagnosed 
CP CML and showed a cumulative 83% incidence of CCyR at 5y (by intention to 
treat analysis) (53). Lower CCyR rates (51% at 2y) have also been reported in a 
smaller population-based study (54). However, despite impressive responses it is 
accepted  that  two  key  problems  with  IM  remain  –  disease  persistence  and  IM 
resistance. 
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Table 1.2 CML disease response definitions 
Haematological response  Cytogenetic response†  Molecular response‡ 
Complete* 
   Plt <450x10
9/L 
   WC <10x10
9/L 
   normal differential 
   spleen not palpable 
Complete 
Partial 
Minor 
Minimal 
None 
Ph+0% 
Ph+1-35%  
Ph+36-65% 
Ph+66-95% 
Ph+>95%  
Complete 
Major 
Undetectable 
<0.10% 
*Peripheral  blood  platelet  count  (Plt)  and  white  cell  count  (WC)  with  normal 
differential implying a lack of immature granulocytes and <5% basophils. †Ph+ as 
%  of  total  metaphases  (at  least  20)  examined  in  bone  marrow.  ‡BCR-ABL  to 
control  gene  ratio. Undetectable levels depend on sensitivity of assay. A major 
response may also be defined as a 3 log reduction from baseline. 
 
1.7.1.1 CML persistence despite imatinib therapy 
IM induces a state of MRD rather than cure. There is clinical evidence for this: the 
number  sustaining  a  CCyR  (66%)  is  far fewer  than  the  number  achieving  this; 
BCR-ABL  transcripts  remain  detectable  in  the  majority  of  patients  (55);  and 
patients who discontinue IM are likely to suffer recrudescence of disease despite 
apparent disease control (56-59).  
 
The source of MRD may be the Ph+HSC. This theory originates from a number of 
in  vitro  and  in  vivo  studies.  Graham  et  al  cultured  CD34+  enriched  fresh 
leukapheresis  products,  taken  at  diagnosis  from  5  patients,  in  the  presence  or 
absence  of  IM.  Although  IM  induced  death  in  dividing  cells,  there  remained  a 
population  of  viable,  quiescent  BCR-ABL+  CD34+  cells,  surviving  despite 
exposure  to  concentrations  of  IM  higher  than  would  be  expected  in  treated 
patients. IM was also antiproliferative, with an increased proportion of cells found 
in the undivided state in the presence of IM and growth factors, as compared to 
when growth factors alone were present (60). Similar conclusions  were reached 
by an independent group (Bhatia et al.) who used CFC and LTC-IC assays with 
primitive  (CD34+38-)  cells  from  patients  newly  diagnosed  with  CML  (61).  In 
addition, quiescent BCR-ABL+ CD34+ cells are insensitive to the effects of Ara-C, 
lonafarnib  (farnesyl  transferase  inhibitor),  LY294002  (PI3K  inhibitor),  17-
allylamino-17-demethoxygeldanamycin (17-AAG, a heat shock protein (HSP) 90 
inhibitor) and arsenic, agents which cause apoptosis in the dividing cell population 
(62,  63).  The  clinical  significance  was  confirmed  by  further  work  with  CD34+   27 
selected BM samples taken from 15 IM treated patients with a CCyR.  Despite a 
confirmed  response  to  IM  in  all,  CFU  and  LTC-IC  assays  demonstrated  that 
functional  BCR-ABL+  progenitor  cells  remained.  In  addition,  there  was  an 
increased  frequency  of  BCR-ABL+  cells  within  the  CD34+  cell  fraction  when 
compared  to  total  BM  mononuclear  cells  (MNC),  indicating  an  enrichment  of 
leukaemic  cells  within this  population, consistent  with  earlier in  vitro  work (64). 
This  work  has  been  extended  and  presented  recently.  It  has  been  shown  that 
BCR-ABL+  primitive  (CD34+38-)  HSC  are  present  in  patients  with  CP  CML  in 
CCyR who have been treated with IM for 5y. Furthermore the BCR-ABL levels in 
this sub-population do not appear to decline during this time (65). The reversibility 
of  the  quiescent  state  which  is  consistent  with  Ph+HSC  persistence  has  been 
demonstrated in a mouse model of CML. BM cells taken from mice with a CML-
like disease, which were treated with and had responded to IM, were transplanted 
into irradiated recipients - all of which then developed disease (66).  
 
1.7.1.2 Imatinib resistance mechanisms 
Response criteria are used to define primary IM resistance and include a failure to 
achieve at least a partial CyR (PCyR) after 12m or a CCyR by 18m therapy (50). 
IRIS trial data show that 16% and 24% respectively do not achieve these targets. 
De Lavallade et al. showed a failure to achieve at least PCyR at 12m in 39% and 
Lucas et al. failure to achieve CCyR by 18m in 51% of treated newly diagnosed 
patients  (53,  54).  Secondary  IM-resistance  is  indicated  by  a  loss  of  previously 
achieved response and will affect approximately 16% of newly diagnosed patients 
in  the  first  3y  of  treatment  (51).  BCR-ABL  kinase  domain  mutations  and  drug 
transport  are  considered  important  resistance  mechanisms,  though  other 
mechanisms  have  been  described,  such  as  amplification  of  the  BCR-ABL 
oncogene (seen in 6% of those with IM resistance (67)). 
 
1.7.1.2.1 BCR-ABL mutations 
Mutations of the BCR-ABL kinase domain are seen in 35-45% patients resistant to 
IM and so have generated particular interest as a cause for treatment failure (67-
70). BCR-ABL mutations are more prevalent in advanced disease stages than in 
early CP and in the majority of patients (57-89%) are associated with acquired IM 
resistance  (70,  71).  Furthermore  the  detection  of  mutations  may  precede  the 
development of resistance and is predictive of relapse. There is also evidence that 
BCR-ABL mutations may be seen in patients prior to initiation of IM therapy and so   28 
may  be  a  cause  of  primary  resistance  (72).  Different  mutations  vary  in  their 
susceptibility to TKI as demonstrated by inhibition of proliferation of transfected 
BCR-ABL+Ba/F3 cell lines (Table 1.3). Of particular scientific significance is the 
T315I mutation. This is a phosphate-binding loop mutation found in all stages of 
CML and is associated with BCR-ABL resistance to all currently available TKI. The 
clinical significance is the subject of some debate. An analysis of 27 patients with 
T315I demonstrated that the 2y-survival (87% in CP patients) was similar to that of 
patients with no/other mutations (73). However disease phase is a well recognised 
indicator  of  prognosis  and  at  the  time  of  detection  with  T315I  the  majority  of 
patients are in AP or BC (74).  
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Table  1.3  Comparative  cellular  proliferation  assays  of  tyrosine  kinase  inhibitor 
treated BCR-ABL+Ba/F3 transfectants 
Imatinib  Nilotinib  Dasatinib   
IC50 
(nmol/L) 
Fold 
change 
IC50 
(nmol/L) 
Fold 
change 
IC50 
(nmol/L) 
Fold 
change 
             
T315I  >6400  >25  >2000  >154  >200  >250 
Y253H  >6400  >25  450  35  1.3  2 
E255V  >6400  >25  430  33  11.0  14 
E255K  5200  20  200  15  5.6  7 
Y253F  3475  13  125  10  1.4  2 
M244V  2000  8  38  3  1.3  2 
F359V  1825  7  175  13  2.2  3 
V379I  1630  6  51  4  0.8  1 
Q252H  1325  5  70  5  3.4  4 
G250E  1350  5  48  4  1.8  2 
F317L  1050  4  50  4  7.4  9 
L387M  1000  4  49  4  2.0  3 
M351T  880  3  15  1.2  1.1  1.4 
H396P  850  3  41  3  0.6  0.8 
F311L  480  4  23  2  1.3  2 
             
WT   260  1  13  1  0.80.  1 
             
Table  adapted  from  reference  (75).  Cellular  proliferation  assessed  at  72h  drug 
incubation by a methane-thiosulfonate based assay. Fold change refers to wild 
type  (WT)  i.e.  p210  BCR-ABL.  Those  mutants  seen  more  commonly  (85%  of 
mutations)  are  highlighted  (█)  (70).  Rows  highlighted  (█)  are  those  mutants 
available to use in this project. 
 
1.7.1.2.2 Resistance through mechanisms other than BCR-ABL mutation 
 
1.7.1.2.2.1 Drug transport - Efflux 
The  ATP-binding  cassette  (ABC)  transporter  family  form  a  large  group  of 
transmembrane proteins involved in many metabolic processes with the capacity 
to  transport  a  variety  of  different  substrates.    There  are  7  subfamilies  (ABCA 
through  to  ABCG).    Expression  of  these  genes  can  be  seen  in  normal  and 
malignant cells.  Members of the ABC family are important in the mechanism of   30 
multidrug  resistance  (MDR)  (reviewed  in  (76)).    MDR  is  the  simultaneous 
development  of  resistance  to  more  than  one  therapeutic  agent  and  can  affect 
drugs  with  different  mechanisms  of  action.  Important  genes  encoding  ABC 
transporters associated with MDR include: ABCB1, encoding P-glycoprotein (Pgp), 
also known as MDR1; ABCC1 with the protein product MRP1; and ABCG2 which 
is also named mitoxantrone-resistance protein or breast cancer resistance protein. 
Of these transporters ABCB1 and ABCG2 have been studied in CML, in particular 
for their role in IM transport.  ABCC1 appears to play a less significant role and will 
not be discussed further (77). 
 
1.7.1.2.2.1.1 P-glycoprotein 
The  importance  of  Pgp  in  a  variety  of  tumour  types  has  been  established 
(reviewed  in  (76))  with  the  contribution  to  drug  resistance  in  CML  under 
investigation.  BCR-ABL+  cell  lines  may  acquire  resistance  through  increased 
expression  of  Pgp  if  cultured  in  vitro  in  titrated  concentrations  of  IM.  This 
resistance may then be overcome through selective inhibition of this transporter 
using verapamil (78, 79).  However these results have not directly translated in the 
clinical setting. Though Pgp inhibitors appeared to restore IM sensitivity in vitro to 
CML cells taken from the BM of 6 patients with IM-resistant BC CML – there was 
no  evidence  found  for  altered  Pgp  expression  (79).    However,  Galimberti  et  al 
demonstrated  that  expression  levels  of  ABCB1  in  33  IM  treated  patients 
distinguished those patients who progressed to advanced phases of the disease 
(80).   
 
It may be that expression of Pgp is a crucial mechanism of IM resistance in a 
select group of patients; alternatively it may be one contributing factor influencing 
others. A novel approach targeting Pgp efflux as a presumed mechanism of IM 
resistance involves use of the HSP90 inhibitor 17-AAG. This compound disrupts 
the  complex  formed  between  HSP90  and  BCR-ABL  resulting  in  increased 
proteasomal  degradation  of  BCR-ABL.  17-AAG  has  also  been  shown  to  inhibit 
Pgp activity, as shown by Rhodamine-123 efflux. This effect was demonstrated by 
Radujkovic et al. who also demonstrated synergy between IM and 17-AAG. This 
was seen in 2 IM-resistant cell lines, when the effects of reducing BCR-ABL levels 
and  activity  and  apoptosis  induction  were  considered.  Synergism  was  not 
apparent in the IM-sensitive cell lines used for comparison. There was an additive 
effect on colony formation by PB MNC samples from 3 IM-sensitive patients in BC.   31 
It  was  concluded  that  diminished  Pgp  activity  may  provide  a  mechanism  for 
increasing intracellular concentrations of IM and so overcome IM resistance (81). 
This work is consistent with that of others, where evidence for an additive effect 
between  17-AAG  and  IM  in  BCR-ABL+  cell  lines  and  CD34+  selected  patient 
samples has been demonstrated. However, the quiescent Ph+HSC population are 
not sensitive to this combination (62). 
 
1.7.1.2.2.1.2 ABCG2 
ABCG2  is  highly  expressed  in  normal  HSC  though  is  downregulated  with 
maturation.  The  function  of  high  ABCG2  expression  is  not  clear  though  it  may 
provide  a  mechanism  for  drug  resistance.  IM  interacts  with  ABCG2  and  initial 
studies  in  BCR-ABL+  cell  lines  suggested  that  IM  was  a  substrate  for  this 
transporter (82).  More recent work on patient samples showed that in common 
with normal HSC, Ph+HSC express ABCG2 at high levels.  IM inhibits the function 
of the transporter in Ph+HSC, shown by the accumulation of ABCG2 substrates 
(BODIPY-prazosin) and radiolabelled mitoxantrone.  Co-exposure of an inhibitor of 
ABCG2 (fumitremorgin C) did not enhance the effect of IM on BODIPY-prazosin 
accumulation, or alter the intracellular accumulation of radiolabelled IM.  This led 
to  the  conclusion  that  IM  is  an  inhibitor  of  ABCG2  and  not  a  substrate  (83).  
Overexpression  of  this  transporter  should  not  therefore  affect  intracellular 
concentrations  of  IM  or  mediate  resistance  to  this  drug.  Similar  results  were 
obtained by another group (84). Others have utilised BC CML and transfected cell 
lines and suggested that high levels of ABCG2 expression do mediate resistance 
to  IM  -  though  interpretation  is  complicated  by  evidence  of  IM  induced 
downregulation of ABCG2  expression (85). The  true answer to the question  of 
ABCG2 involvement is of significance as this transporter may serve as a future 
target for drug and antibody therapy.   
 
1.7.1.2.2.2 Drug transport - Uptake 
IM  is  transported  actively  into  cells  by  the  human  organic  cation  transporter  1 
(hOCT1). This protein is a member of the solute carrier superfamily and organic 
cation transporter (OCT) subfamily. Treatment of CP CML samples with OCT-1 
inhibitors (prazosin and procainamide) affects intracellular uptake and retention of 
IM (86).  Furthermore, the concentration of IM retained within the cell correlates 
with kinase inhibition  (derived from Crkl phosphorylation).   This  is of  relevance 
clinically  as  the  sensitivity  of  BCR-ABL  kinase  inhibition  to  IM  correlates  with   32 
clinical outcome at 12 months (87). These results may not be translated directly to 
other TKI as nilotinib does not appear to be transported by OCT-1, presumably 
due to structural differences.  
 
1.7.2 Second-generation TKI 
 
1.7.2.1 Dasatinib 
Dasatinib (Sprycel®, Bristol-Myers Squibb, New York, USA) was approved in 2007 
for treatment of patients in Scotland with CP CML resistant to or intolerant of IM 
(www.scottishmedicines.org.uk). Dasatinib is one member of a family of dual ABL- 
and  SRC-family  kinase  (SFK)  inhibitors.  SFK  (in  particular  LYN  and  HCK)  are 
downstream targets of BCR-ABL. However in IM-resistant patient samples and cell 
lines it has been shown that SFK may be active despite BCR-ABL inhibition and 
so support cell survival (88). Dasatinib binds the ATP-binding site of ABL in the 
inactive  or  active  conformation  –  IM  binds  and  stabilises  only  the  inactive 
formation  (89).  In  addition,  dasatinib  more  potently  inhibits  BCR-ABL  kinase 
activity  than  IM  and  effectively  inhibits  cell  growth  of  cell  lines  expressing  IM-
resistant  BCR-ABL  mutations.  However,  it  is  not  effective  against  the  T315I 
mutation (90).  
 
Clinical data from trials of dasatinib have been published. For those with CP CML 
and IM-resistance or intolerance best observed responses were 91% (CHR) and 
49% (CCyR). Of interest is that 74% of these patients were IM-resistant and 40% 
had a confirmed BCR-ABL mutation (91). Recent extended follow-up from this trial 
has been presented and responses appear durable with 86% maintaining a CCyR 
once achieved (92). However, as with IM, BCR-ABL transcripts remain detectable 
in  37-56%  of  patients  at  2y  (93).  Responses  are  also  gained  in  patients  with 
advanced stage CML. The phase 2 AP trial achieved a 24% CCyR in IM intolerant 
or resistant patients with responses seen in patients with  a range of BCR-ABL 
mutations. However, as predicted by in vitro data, patients with T315I (or F317L) 
failed to respond (94).  
 
1.7.2.2 Nilotinib 
Nilotinib (Tasigna, AMN107, Novartis Pharma, Basel, Switzerland) was approved 
in 2008 for treatment of patients in Scotland with CP CML resistant to or intolerant 
of IM (www.scottishmedicines.org.uk). Nilotinib is a TKI designed on the molecular   33 
framework of IM. Analysis of the crystal structure of nilotinib-ABL complexes show 
that like IM, the drug binds to the inactive conformation of ABL though with subtle 
alterations  in  structure  allowing  a  better  topographical  fit.  Pre-clinical  data 
confirmed the in vitro efficacy of this drug in IM-sensitive and resistant cell lines 
with complementary in vivo data from a murine CML model (95). Clinical trials in 
CP CML with IM-intolerance or resistance have been published and show 74% 
and 31% achieve a CHR or CCyR respectively (96) (updated to 77 and 42% with 
2y follow-up (97)). Responses appear durable with 84% of those with either CCyR 
or  MCyR  maintaining  this.  42%  of  these  patients  had  BCR-ABL  mutations, 
however those with particular mutations including T315I, Y253F and E255V failed 
to respond. Few responses are seen in advanced phases of the disease, with 26% 
or 16% achieving a CHR or CCyR respectively (98).  
 
1.7.2.3 Front line use of second generation tyrosine kinase inhibitors 
Early  phase  2  trial  data  suggests  that  use  of  the  more  potent  TKI  as  first-line 
therapy may achieve more rapid response than IM. The rationale for this is based 
on  analysis  of  the  IRIS  trial  data  which  demonstrated  that  achievement  of 
particular milestones – in particular CCyR at 12m and major molecular response 
(MMolR)  at  18m  –  are  associated  with  a  low  risk  of  disease  progression  (51). 
However  despite  impressive  early  responses  (96/98%  achieving  CCyR  with 
nilotinib/dasatinib) disease eradication is not achieved with detectable BCR-ABL 
transcripts in the majority (99, 100).  
 
1.7.2.4 Tyrosine kinase inhibitors in combination 
There  is  no  significant  cross  resistance  between  nilotinib  and  dasatinib,  with 
significant responses seen in a published series of patients with disease refractory 
to  both  IM  and  nilotinib  therapy.    Cytogenetic  responses  were  seen  in  31%  of 
these patients, though the durability of response is not clear with limited follow up 
data so far available (101). Therefore there may be benefits to be gained from the 
combination  of  IM  with  either  dasatinib  or  nilotinib  as  all  3  drugs  appear  to 
predispose  to  the  development  of  different  BCR-ABL  mutation  profiles  (102).  
Synergism of IM and nilotinib has been demonstrated in a variety of cell lines and 
a  murine  model  of  CML,  however  predictably  the  T315I  mutation  remained 
resistant (103)   
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1.7.2.5 Second generation tyrosine kinase inhibitors and the stem cell 
It is clear that currently available TKI are unable to treat CML where particular 
BCR-ABL mutations are found. There is also concern that the quiescent Ph+HSC 
population are insensitive to these drugs. It has been demonstrated in vitro using 
dasatinib  that  despite  potent  inhibition  of  BCR-ABL  activity  (using  Crkl 
phosphorylation as a marker), a quiescent population of primitive Ph+HSC persist 
– despite the confirmed absence of BCR-ABL mutations (4). In a similar series of 
experiments tracking division of CD34+ CML cells in the presence of nilotinib, it 
was  seen  that  quiescent  Ph+HSC  persist  and  may  accumulate  relative  to 
untreated cells which will tend to divide and differentiate (104). 
 
1.8 The need for new approaches 
Within the leukaemic HSC population evidence is presented for a population of 
cells which are relatively insensitive to current TKI and characterised by phenotype 
(CD34+38-) and quiescence. This population will serve to sustain MRD, despite 
apparent  adequate  response  to  therapy.  Patients  will  therefore  remain  on  drug 
indefinitely for fear of disease recrudescence, and so with long-term therapy there 
is  the  theoretical  risk  that  selection  of  resistant  mutations  (such  as  T315I)  will 
occur. However it is accepted that longer term data from the IRIS trial supports the 
stance  that  MRD  in  the  majority  is  of  no  consequence  as  once  significant 
responses  (MMolR)  are  obtained  they  appear  durable  with  very  few  patients 
suffering  disease  progression.  The  only  “curative”  option  remains  haemopoietic 
stem cell transplantation, a procedure limited in application by donor availability 
and the toxicity of conditioning regimes. The success of TKI has led to a significant 
reduction  in  the  popularity  of  transplantation  for  CML  and  it  is  now  an  option 
reserved in most UK centres for those with advanced stage disease (105).   
 
A number of different strategies are being adopted to improve the treatment of 
CML  and these  are outlined in Table  1.4  and  have  been  reviewed  (106). This 
introduction will focus on proteasome inhibition as a therapeutic strategy to target 
CML. 
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Table 1.4  Strategies to target imatinib resistance and disease persistence. 
Target  mechanism  examples  reference 
       
BCR-ABL       
Activity  newer  tyrosine  kinase 
inhibitors 
dasatinib, 
nilotinib 
Reviewed here 
Stability  histone  deacetylase 
inhibitors 
LBH-589  (107) 
  heat  shock  protein  90 
inhibitors 
geldanamycin 
17-AAG 
(107-110) 
enhance IM effects  increased IM dose    (111-114) 
  combination  of  IM  with 
IFN-A 
SPIRIT trial  (115) 
  G-CSF scheduling  GIMI trial  (116) 
  drug efflux inhibition  verapamil  (79,  81,  117, 
118) 
BCR-ABL location  nuclear trapping  leptomycin B  (119, 120) 
       
alternative targets       
  proteasome inhibitors  bortezomib  Reviewed here 
  farnesyl  transferase 
inhibitors 
lonafarnib, 
BMS-214662 
(121) 
  protein kinase C  bryostatin  (122) 
  reactive oxygen species 
generation 
adaphostin  (123, 124) 
  hypusination inhibitors  ciclopirox  (125) 
  aurora kinase inhibitors  MK-0457  (126-128) 
       
 
 
1.9 The proteasome 
The  proteasome  is  an  intracellular  organelle  which  functions  as  a  targeted 
mechanism for protein degradation. Through  this  it  plays  a  vital  role in cellular 
processes such as cell cycling, adhesion, proliferation and apoptosis – all of which 
may  be  deregulated  in  cancer.  An  outline  of  the  mechanism  of  proteasome 
function is illustrated in Figure 1.3. 
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Figure 1.3 An illustration of proteasome activity.  
TNFα (tumour necrosis factor-alpha) and IFNγ (interferon-gamma). 
 
The 26S proteasome is formed from a 20S core with two 19S regulatory cap units. 
Proteins are targeted for proteasomal degradation by the attachment of ubiquitin - 
this process following a series of catalytic reactions. Ubiquitin activating enzyme 
(E1) first binds to and activates ubiquitin, which is then transferred to one of a 
group  of  ubiquitin  conjugating  enzymes  (E2).  Ubiquitin  protein-ligase  enzymes 
(E3) then catalyse the binding of E2-bound ubiquitin to the target protein. Through 
multiple reactions a  polyubiquitin tag is formed on the substrate which  enables 
recognition by a proteasome cap unit. There are around 1000 different E3 ubiquitin 
ligases in the human genome and this step provides substrate specificity to the 
process. Furthermore, deregulation of E3 ubiquitin ligase activity is seen in human 
cancer (129). Following recognition by the cap unit, the ubiquitinated substrate is 
presented to the catalytic sites within the 20S core. The core comprises 4 stacked 
rings. Each ring is divided into 7α (α-ring) or 7β (β-ring) subunits.  The α-rings are 
associated with the cap units and act as gated channels.  Catalytic activity occurs 
on  the  β-rings  as  3  peptidase  activities  (CT-L,  tryptic  (T-L)  and  postglutamyl 
peptide hydrolytic (PG)) and each activity is associated with a specific beta subunit 
(β5, β2 and β1 respectively) (reviewed in (130)).   
 
The substrate specificity of the β subunits is modified following stimulation with 
interferon-gamma  or  tumour  necrosis  factor-alpha  and  the  designation  of  the 
subunits  becomes  β1i,  β2i  and  β5i  –  the  proteasome  is  then  an 
immunoproteasome.  This  functional  change  enhances  the  ability  of  the  cell  to 
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present  antigenic  peptides  via  MHC  class  I.    There  is  some  evidence  that  the 
immunoproteasome activity may predominate in certain types of haematological 
malignancy (131).  This change may be of significance when the measurement of 
proteasome activity is considered. 
 
1.9.1 Measuring proteasome activity 
Proteasome  activity  is  conventionally  measured  by  the  turnover  of  fluorescent 
substrates  for  the  3  catalytic  sites  and  results  are  expressed  as  released 
fluorescence  units.  Though  widely  adopted,  it  is  recognised  that  there  are 
limitations to this technique: cell  lysis  prior  to analysis is  required and it is  not 
known how this will interfere with proteasome activity; immunoproteasome activity 
is not assessed by this method; and large numbers of cells (>1x10
7) are required. 
More recently, methods have been established using labelled compounds which 
act  as PI and probe  specific subunit activities in cell lysates (131)  or live cells 
(132).  This  permits  more  detailed  analysis  of  both  proteasome  and 
immunoproteasome  activity using relatively  small cell numbers. However, these 
are  not  commercially  available.  Activity  may  also  be  determined  by  indirect 
methods such as effects on pathways shown to be intimately associated with the 
proteasome for example the NFkB/IkB axis.  
 
1.9.2 Proteasome inhibitors and cancer 
Cancer  cell  lines  have  abnormally  high  levels  of  proteasome  activity  and 
expression  (133)  and  have  been  shown  to  be  relatively  more  sensitive  to  the 
effects of PI than their non-malignant counterparts. The first proteasome inhibitor 
to enter clinical trials was bortezomib (Velcade®, Janssen-Cilag International NV, 
Beerse, Belgium) and this remains the only PI approved for clinical use. It was 
licensed for use in Scotland in 2004 for patients with multiple myeloma who have 
received at least two prior therapies and who are refractory to alternative licensed 
treatments (www.scottishmedicines.org.uk). In addition bortezomib was licensed in 
the  USA  in  2006  for  second-line  use  in  patients  with  mantle  cell  lymphoma 
(www.fda.gov) and may be used in this disease in the UK within the context of a 
clinical trial (www.cancerhelp.org.uk). In the setting of two phase 1 clinical trials 
including Australia, Estonia and USA, NPI-0052 is a new PI under investigation for 
treatment of advanced malignancy including multiple myeloma. Carfilzomib (PR-
171) is a further PI which has shown evidence for efficacy in multiple myeloma and   38 
mantle cell lymphoma and which is available for use in these conditions in open 
clinical trials. (National Cancer Institute, www.cancer.gov). 
 
1.9.3 Bortezomib 
In 1999 the National  Cancer Institute tested a selection of related boronic acid 
derivative  PI  for  activity  in  a  variety  of  cancer  cell  lines.  Of  these,  bortezomib 
(formally  PS-341)  demonstrated  particular  efficacy  based  on  potency  of 
proteasome  inhibition  (using  fluorescence-based  assays)  and  ability  to  inhibit 
cancer cell growth. The prostate cancer cell line PC-3 was selected from this initial 
study for more detailed investigation. It was shown in vitro that the concentration 
required to kill 50% of PC-3 cells at 48 hours (h) was 20nM. This compound also 
inhibited growth of tumours in mice when used at a concentration of 1.0mg/kg with 
comparable and detectable levels of radiolabelled drug in the PB and BM (134). 
The activity of bortezomib is relatively selective for CT-L activity and this has been 
confirmed by fluorometric and subunit probe-based assays (131). Laboratory and 
clinical  investigations  have  been  extended  by many  other  groups  using tumour 
models  and  cell  samples  from  patients  with  haematological  and  solid  organ 
malignancies.  It  is  from  these  studies  that  a  mechanism  of  action  has  been 
proposed  and  pharmacodynamic  and  pharmacokinetic  information  has  been 
established. 
 
1.9.4 Proposed mechanism of proteasome inhibitors 
The proteasome is found in all eukaryotic cells, both malignant and non-malignant. 
A PI must therefore exploit a difference in activity and/or reliance of the cell upon 
that activity if it is to be selective. The state of cancer is generally accepted to 
involve  an  imbalance  between  those  factors  driving  proliferation  and  those 
promoting  apoptosis.  It  is  likely  that  PI  “tilt  the  scales”  from  cell  survival  to 
apoptosis in malignant cells by a number if ways. A complete mechanism of action 
is not yet known fully and may vary between different cell types utilising abnormal 
proteasome activity in different ways. 
 
1.9.4.1 The NFkB/IkB axis 
NFkB is a transcription factor that serves to support cell survival. This is achieved 
by  promoting  expression  of  anti-apoptotic  genes  as  well  as  those  influencing 
inflammation, proliferation and differentiation. Regulation of NFkB activity is well 
described  and  is  illustrated  in  Figure  1.4.  NFkB  exists  as  a  cytoplasmic  form   39 
bound  to  an  inhibitory  molecule  IkB.  The  principal  pathway  leading  to  NFkB 
activation is the phosphorylation of IkB by IkB kinase (IKK). IkB is ubiquitinated 
and degraded by the proteasome. NFkB may then enter the nucleus and bind to a 
specific consensus site within DNA. Furthermore, IkB transcription is activated by 
NFkB  leading  to  loss  of  NFkB  from  the  nucleus  and  enabling  negative 
autoregulation of the pathway (reviewed in (135)). The structure of the proteins 
involved is more complex than has been illustrated.  ‘NFkB’ is commonly used to 
describe a family of proteins which form homo- and heterodimers, the most well 
characterised  form  being  p50/p65.  The  family  of  anchorin-domain  containing 
inhibitory molecules binding NFkB and preventing nuclear translocation (termed 
‘IkB’ in Figure 1.4) include IkBα, IkBβ, IkBγ, IkBαε, bcl-3, p105 and p100. IKK 
consists  of  IKKα,  IKKβ,  and  IKKγ  (together  referred  to  as  NFkB  essential 
modulator subunits).   
 
 
Figure 1.4 An illustration of the NFkB/IkB axis 
 
When  the  role  of  this  pathway  in  proliferation,  apoptosis  and  inflammation  is 
considered,  it  is  not  surprising  that  constitutive  NFkB  activity  has  been 
demonstrated in many malignancies, including CML (136-138). Relevant to CML is 
the  finding  that  NFkB  is  required  for  tumour  development  and  primary  BM  cell 
transformation  by  BCR-ABL+  cell  lines  (17)    NFkB  activation  may  occur 
downstream  of  BCR-ABL  with  suggested  mechanisms  involving  BCR-ABL 
activation of serine-threonine kinases such as PKD2 (mediating activity through 
the  IKK  pathway)  (137)  and  MEKK  (139).    BCR-ABL  may  also  increase  the 
degradation of IkB through an undefined mechanism independent of IKK (138).  . 
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There is evidence for constitutive activation of NFkB in samples from patients with 
CML. PB and BM were taken from 17 patients with CML (15 CP, 2 myeloid BC) 
and  analysed  by  electrophoretic  mobility  shift  assays  (EMSA)  a  standard 
measurement of nuclear NFkB activity. In both BC (but not in CP) a significant 
increase  in  activity  was  seen  in  comparison  to  healthy  controls  (140).    These 
findings  were confirmed in a separate study analysing PB from 8 patients with 
CML BC by EMSA. Here the activity was unaffected by exposure of patients to IM, 
which is surprising when considering the evidence for BCR-ABL mediated NFkB 
activation (138).   
 
1.9.4.2 Bortezomib and the cell cycle 
The  cell  cycle  is  a  regulated  and  ordered  process  of  growth  and  division.  It  is 
conventionally divided into 4 sequential phases: G1, a synthetic phase; S phase, 
during  which  DNA  duplication  occurs;  G2,  a  second  synthetic  phase;  and  M 
phase, during which the cell undergoes mitosis. The progression through these 
phases is controlled by cyclin dependent kinases (CDK), which are expressed and 
degraded at various points of the cell cycle. Cyclins are regulatory proteins which 
form a complex with CDK and are necessary for kinase activity. An illustration of 
the cell cycle is shown (Figure 1.5) demonstrating the function of various cyclin-
CDK complexes. 
 
 
Figure 1.5 An illustration of the role of the cyclin - cyclin dependent kinase (CDK) 
complex  (white  text  boxes)  and  CDK  inhibitors  (blue  text  boxes)  in  cell  cycle 
progression through 4 key phases  (grey text  boxes)  with corresponding check-
points (black bars). 
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The retinoblastoma protein is (pRb) is of key importance for cell cycle initiation. 
pRb associates with E2F family of transcription factors and inhibits their activity. 
Phosphorylation  of  pRb  leads  to  dissociation  of  the  pRb-E2F  complex.  This 
phosphorylation is mediated by cyclin-CDK complexes (cyclin D–CDK3, cyclin D-
CDK6 and cyclin E-CDK2). E2F transcription factors which have been released 
from  inhibitory  binding,  promote  the  expression  of  genes  necessary  for 
progression  from  G1  to  S  phase.  Transition  through  S  phase  requires  the 
repression  of  E2F  activity  and  this  involves  Cyclin  A–CDK2  and  CDK1.  The 
phosphorylation inhibits the DNA binding of the E2F. Transition through G2 into M 
phase requires the activity of cyclin B–CDK1 complexes. A further level of control, 
in  particular  during  the  G1  and  S  phase,  is  provided  by  the  cyclin  dependent 
kinase  inhibitors  (CDKi).  There  are  two  families  of  CDKi  -  the  Cip/Kip  family 
(p21
cip1/waf1, p57
kip2 and p27
kip1) which inhibit the kinase activities of cyclin D-, E-, 
A- and B-CDK complexes, and the INK4 family which inhibit cyclin D-CDK4 and 
CDK6 complexes (141). Cell cycle transition is therefore mediated through loss of 
CDKi  activity  permitting  progression  and  increased  activity  resulting  in  growth 
arrest.  This  may  be  illustrated  by  studies  where  p27
kip1  was  over-expressed  in 
human cells with consequent G1 arrest (142).   
 
CDKi  and  the  Cip/Kip  family  in  particular  are  frequently  deregulated  in  human 
malignancies and may be of prognostic value (143). It has been shown that BCR-
ABL+  cell  lines  have  reduced  levels  of  p27
kip1  and  this  appears  to  be  partially 
regulated  by  proteasomal  degradation.  A  suggested  mechanism  involves  BCR-
ABL regulated expression of SKP2 - this then influences ubiquitination (as part of 
a  multiple  component  complex  with  E3  ubiquitin  ligase  activity)  and  hence 
proteasomal degradation of the p27
kip1. It has recently been shown in cell lines that 
BCR-ABL induces phosphorylation of p27
kip1 at the Y88 position and so promotes 
ubiquitination and subsequent  degradation - exploiting a mechanism for normal 
cell cycle progression into S-phase (144). Correspondingly it has been seen that 
BCR-ABL inhibition (with IM) in cell lines and CD34+ cells from patients with CML, 
results in p27
kip1 stabilisation and increased apoptosis (145). Furthermore, induced 
over-expression of p27
kip1 in BCR-ABL+ cell lines reduces proliferation rates, with 
accumulation  in  G1  phase  and  this  renders  cells  insensitive  to  PI  induced 
apoptosis. It is also speculated, though unproven, that increased p27
kip1 may be a 
mechanism for drug resistance in the quiescent stem cell population (146). The 
CDKi  p21
cip1/waf1  and  p57
kip2  and  are  related  to  p27
kip1  and  presumed  to  share   42 
similar activity. Treatment of BCR-ABL+ and lung cancer cell lines with bortezomib 
is associated with stabilisation of p21
cip1/waf1 and accumulation of cyclin B (147, 
148). p57
kip2 is regulated in a  similar  manner to  p27
kip1 through  SKP2 ubiquitin 
ligase activity and proteasomal degradation (149). However, effects of bortezomib 
on p57
kip2 have not specifically been addressed in CML.  
 
Bortezomib has established antiproliferative effects in cell lines and tumour cells 
from solid organ and haematological malignancies including BC CML. This has 
been demonstrated with accumulation of treated cells in G2-M phase (1, 9, 150). It 
is  likely  ineffective  cell  division  is  mediated  by  a  failure  of  the  normal  cyclical 
degradation  of  CDK  complexes  and  CDKi  and  it  is  presumed  the  increased 
proliferative potential of malignant cells renders them more susceptible to these 
effects than their non-malignant counterparts. 
 
1.9.4.3 Bortezomib and apoptosis 
Apoptosis  describes  a  coordinated  process  by  which  cells  die.  Apoptosis  is 
initiated in several ways and of most importance are the “extrinsic” and “intrinsic” 
pathways. Extrinsic apoptosis is precipitated by the binding of a ligand (e.g. TNF) 
to  a  cell  surface  death  receptor  (e.g.  TNF  –related  apoptosis  inducing  ligand, 
TRAIL receptor). In intrinsic apoptosis, cell death follows a series of intracellular 
events.  Both  pathways  result  in  the  characteristic  changes  of  cell  shrinkage, 
chromatin  condensation,  nuclear  fragmentation,  blebbing  and  the  exposure  of 
phosphatidyl  serine  on  the  outer  cell  membrane.  The  latter  is  exploited  in 
experimental  techniques  demonstrating  cell  death  (2.4.2).  Cysteine  protease 
cleaving  after  Asp  (‘caspase’)  enzymes  are  important  in  apoptosis  and  are 
synthesised as an inactive pro-caspase requiring specific cleavage for activation. 
This  cleavage  is  inhibited  by  inhibitor  of  apoptosis  (IAP)  proteins.  In  general 
“initiator” caspases (e.g. caspases-8,-9 and  -10)  activate “executioner” capases 
(e.g. caspase-3 (2.4.3) and -7) which then precipitate apoptosis.  
 
The  extrinsic  pathway  is  stimulated  by  death  receptor  binding  with  consequent 
activation of caspases-8 and -10 through the adaptor molecule FAS-associated 
death domain-containing protein (FADD). In the intrinsic pathway the initiator is 
caspase-9, which is activated by formation of a complex with apoptosis protease 
activating factor-1 (APAF-1). This process requires cytochrome c release from the 
mitochondrion by membrane permeabilisation (MMP). With MMP, Cytochrome c   43 
release  is  accompanied  by  second  mitochondria-derived  activator  of  caspase 
(SMAC)  which  binds  and  deactivates  IAP  (151).  MMP  is  considered  a  critical 
phase of apoptosis and is influenced by the BCL-2 family of proteins, all members 
of  which  contain  BCL-2  homology  (BH)  domains.  They  are  either  anti-  or  pro-
apoptotic.  Anti-apoptotic  factors  include  BCL-2,  BCL-XL  and  MCL-1.  The  pro-
apoptotic  members  are  subclassified  as  those  with  multiple  BH  domains  (e.g. 
BAX,  BAK)  or  only  one  (BH-3  only)  domains  (e.g.  BIM,  BID,  BAD,  NOXA  and 
PUMA).  Fundamental  to  MMP  is  the  formation  of  molecular  pores  in  the 
mitochondrial membrane and this is directly associated with the activation of BAX 
and BAK. BH3 only proteins indirectly contribute to this activity by either activation 
of BAX/BAK or by blocking the inhibitory activity of anti-apoptotic BCL-2 proteins. 
 
Though  the  two  pathways  are  described  separately,  there  is  recognised  cross-
activation.  For  example,  TRAIL-stimulated  caspase-8  activation  mediates 
cleavage and activation of BID with resulting Cytochrome c release - hence linking 
the extrinsic and intrinsic pathways (152). 
 
Bortezomib has been shown to affect the balance of pro- and antiapoptotic factors. 
A key member of the BH3-subgroup of pro-apoptotic factors is BIM.  BCR-ABL 
may reduce BIM via ERK activity with resulting phosphorylation and proteasomal 
degradation. This influence on levels of BIM has been reversed with IM, nilotinib 
and  PI  exposure.    Furthermore,  siRNA  reducing  expression  of  BIM  has  been 
shown to rescue cells and the BH3-mimetic ABT-737 enhanced IM-induced cell 
death.    These  results  have  been  generated  from  work  with  IM-sensitive  and 
resistant cell lines and CML patient samples and have led to the suggestion that PI 
may be effective in combination with TKI (153-156). Other pro-apoptotic factors 
affected by bortezomib in various solid organ cell line models include NOXA (157, 
158) and BIK (though at 100-500nM bortezomib) (159). Effects have been seen on 
anti-apoptotic factors with possible upregulation of BCL-2 though this has not been 
a consistent finding (159). Full activation of BIM, BAK and BAK requires loss of 
MCL-1  through  proteasomal  degradation.  In  CML  cell  lines  MCL-1  has  been 
demonstrated as constitutively active - when targeted with siRNA to reduce MCL-1 
activity,  cells  undergo  apoptosis.  It  is  interesting  to  note  in  melanoma  cells 
bortezomib treatment may enhance or stabilise MCL-1 by preventing breakdown 
(160). This observation is however consistent with the concept that PI shift the   44 
balance towards apoptosis by influencing a number of factors rather than specific 
targeting of individual pathways. 
 
1.9.4.4 Bortezomib and reactive oxygen species generation 
Reactive oxygen species (ROS) are products of normal cellular processes and are 
involved in the initiation of apoptosis through stimulation of cytochrome c release. 
In the resting state ROS are stabilised through antioxidants such as glutathione. 
However  following  a  disruption  of  the  MMP  there  is  an  associated  increased 
generation  of  ROS,  saturating  the  antioxidant  systems  and  resulting  in  the 
promotion  of  cell  death  (“bioenergetic  crisis”)  (reviewed  in  (151)).  Bortezomib 
treatment of non-small cell lung cancer cell lines at 50-100nM is associated with 
enhanced  generation  of  ROS.  Inhibition  of  this  ROS  generation  (with  the 
antioxidant  Tiron)  reduced  ROS  generation  and  apoptosis  (161).  In  a  similar 
manner 5nM bortezomib induced ROS generation in BCR-ABL+ Ba/F3 cells (p210 
and T315I) with associated apoptosis which was partially reversed with antioxidant 
treatment (123).  
 
Adaphostin  is  a  member  of  the  tyrophostin  group  of  TKI.  These  compounds 
interfere  with  peptide  binding,  in  contrast  to  IM  which  affects  the  kinase  ATP 
binding  site.  Adaphostin  is  a  derivative  of  AG957,  a  drug  developed  as  an 
alternative  to  IM.  Adaphostin  has  been  shown  to  induce  apoptosis  and  reduce 
BCR-ABL  expression  in  cell  lines.  The  mechanism  of  action  may  involve  the 
generation  of  ROS.  Recent  work  has  produced  results  in  cell  lines  suggesting 
synergism with adaphostin and bortezomib, presumably related to the response to 
oxidative injury (123).  Minimal toxicity of adaphostin on normal  human CD34+ 
cells was seen (124).  
 
1.9.4.5 Bortezomib and autophagy 
Autophagy is a pathway to cell death that is distinct from apoptosis. It is a process 
through which portions of the cytoplasm are enveloped and bound within the cell 
and then the contents digested by lysosomal enzymes. This enables elimination of 
abnormal  intracellular  proteins  or  damaged  organelles.  The  process  may  be 
progressive  with  resultant  destruction  of  the  entire  cell  (reviewed  in  (151)).  Of 
relevance to the proteasome is that the pathway is an additional mechanism for 
protein  degradation,  though  it  involves  aggregation  of  the  abnormal  proteins 
(aggresome)  and  requires  histone  deacetylase  (HDAC)  activity.  Studies  have   45 
shown that targeting of both the proteasome (with bortezomib) and the aggresome 
pathway  (by  tubacin  a  HDAC  inhibitor)  in  multiple  myeloma  PB  and  BM  cells 
results  in  synergistic  accumulation  of  polyubiquitinated  proteins  and  apoptosis 
even  in  the  presence  of  supportive  stromal  cells  (162).  Bortezomib  also  was 
synergistic with LBH589 (a HDAC inhibitor) in multiple myeloma BM and PB cells 
though  here  evidence  was  presented  for  the  role  of  inhibition  of  aggresome 
migration through tubulin deacetylase inhibition preventing autophagy (103). There 
is relevance here to CML as it has been demonstrated that TKI induce autophagy 
in BCR-ABL+ cells. This may be a protective response as concomitant exposure of 
cells to drugs which inhibit autophagy enhanced TKI induced cell death (163, 164). 
Suberoylanilide hydroxamic acid (SAHA, Vorinostat) is a HDAC inhibitor which is 
currently  under  investigation  in  clinical  trials  for  haematological  and  non-
haematological  malignancies,  including  BC  CML.  The  mechanism  of  action 
includes both induction of apoptosis and autophagy, demonstrated by caspase-3 
activation  and  characteristic  morphological  changes  seen  under  electron 
microscopy of HeLA cells (165). Treatment of BCR-ABL+ cell lines and patient BM 
samples, including those expressing T315I, with SAHA resulted in apoptosis that 
was independent of BCR-ABL activity. Apoptosis was enhanced when SAHA was 
used  in  combination  with  drugs  known  to  target  autophagy,  which  include 
chloroquine. 
 
1.9.5 Current clinical use of bortezomib 
 
1.9.5.1 Multiple myeloma 
Particular biological features of multiple myeloma (a malignant disorder of plasma 
cells) justified in vitro experiments exposing cell lines and BM cells from patients 
with this condition to bortezomib. In multiple myeloma IL-6 promotes growth and 
survival of the tumour cells and secretion of IL-6 is dependent on NFkB activity 
(166, 167) – as described (1.8.1.2.1) NFkB activity and proteasomal function are 
intricately  connected.  With  bortezomib  treatment,  selective  apoptosis  and 
significant inhibition of cell growth was seen in comparison to normal PB MNC. 
Phase 1 clinical trials demonstrated particular efficacy in plasma cell dyscrasias 
(168) and phase 2 (169, 170) trials in multiple myeloma the safety and efficacy of 
a  1.3mg/m
2  dosing  regime  with  additive  benefits  seen  when  bortezomib  was 
combined  with  dexamethasone.  These  findings  formed  the  basis  of  the 
randomised phase 3 APEX (Assessment of Proteasome Inhibition for Extending   46 
Remissions)  trial  which  compared  bortezomib  monotherapy  with  high-dose 
dexamethasone in patients with relapsed multiple myeloma (171). Bortezomib was 
associated with higher response rates, a longer time to disease progression and 
improved  survival.  Data  from  these  clinical  trials  led  to  the  acceptance  by  the 
Scottish  Medicines  Consortium  for  restricted  use  of  bortezomib  in  multiple 
myeloma as described (1.8).  
 
1.9.5.2 Mantle cell lymphoma 
The  USA  licensing  for  bortezomib  in  relapsed  or  progressive  mantle  cell 
lymphoma is based on supportive data generated from the phase 2 PINNACLE 
(Proteasome  Inhibition  as  an  Innovative  Approach  to  Relapsed  Mantle  Cell 
Lymphoma a Single Agent Evaluation) trial. Here a similar dosing schedule to that 
of the APEX trial was seen to be safe and effective with approximately one-third of 
patients achieving a reduction in tumour burden (172). No submission has been 
made for a UK license for use in this setting though the drug is available for use as 
part of a clinical trial (www.cancerhelp.org.uk). 
 
1.9.5.3 Other haematological malignancies 
There  are  currently  (December  2008)  194  open  and  recruiting  trials  using 
bortezomib for treatment of cancer patients. 10 trials involve treatment of patients 
with AML and of these 1 will accept patients with BC CML. All involve bortezomib 
as combination therapy. 
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Table 1.5 Current clinical trials with bortezomib in myeloid malignancy 
Disease  Trial phase  Additional therapies  Trial number 
AML  1/2  mitoxantrone + etoposide  NCT00410423 
AML  1/2  fludarabine + idarubicin + G-
CSF 
NCT00651781 
AML  2  tipifarnib  NCT00510939 
AML  2  idarubicin + ara-C or 
etoposide + ara-C 
NCT00666588 
AML  2  daunorubicin and ara-C  NCT00742625 
AML and CML-BC  1  tipifarnib  NCT00383474 
AML  1  idarubicin  NCT00382954 
AML  1  azacytidine  NCT00624936 
AML   Not stated  melphalan  NCT00789256 
AML  1  decitabine  NCT00703300 
 
1.9.6 Pharmacodynamics of bortezomib 
A number of clinical trials with bortezomib in solid organ (renal, colon, lung, breast, 
prostate,  neuroendocrine  and  hepatocellular  cancers)  and  haematological  (both 
lymphoid  and  myeloid)  malignancies  have  published  and  the  particular 
pharmacokinetic  features  of  this  drug  are  described.  Following  intravenous 
administration in a phase 1 trial the plasma bortezomib concentration followed a 
biphasic  elimination  profile,  with  an  initial  half  life  <30  minutes.  The  plasma 
concentration of bortezomib varied from a peak of 1.5-7.5ng/mL at 1h and did not 
clearly correlate with proteasome inhibition measured in PB. The conclusion drawn 
was  that  plasma  levels  of  drug  may  not  a  reliable  method  for  predicting  or 
measuring drug effect (173).  Millennium Pharmaceuticals provide data indicating 
a wide range of peak plasma concentrations (109-1300ng/mL) with the caveat “the 
pharmacokinetics  of  Velcade®  as  a  single  agent  have  not  been  fully 
characterised”  (www.velcade.info).  Myeloma  patients  (n=23)  were  specifically 
assessed for pharmacokinetic and pharmacodynamic data. Patients were treated 
with 1.3mg/m
2 (standard dose) following a standard schedule and at day 11 of 
cycle 3 peak levels of 114.9±98.3ng/mL (299nM) and area under the curve at 48h 
of  85.2±18.7ng.h/mL  (approximately  equivalent  to  5.3±1.2nM  continuous 
exposure)  were  recorded  (174).  The  majority  of  published  trials  rely  on  a 
standardised  fluorometric  method  to  determine  a  CT-L:T-L  ratio  and  from  this 
derive data on achieved levels of proteasome inhibition in PB cells (175).  From   48 
animal data >80% proteasome inhibition is predictive of significant morbidity and 
mortality  (134,  176),  this  data  was  extrapolated  to  clinical  trials  to  predict  a 
maximum tolerated dose of 1.96mg/m
2 (177).  The current recommended dose is 
1.3mg/m
2  twice  weekly  for  2  weeks  followed  by  a  10  day  rest  period.    This 
approximates  70-83%  maximal  proteasome  inhibition  at  1h  (168,  173,  174).  
Following peak levels of inhibition at 1h approximately 50% and <20% of peak 
activity  are  seen  at  24  and  72  hours  (h)  respectively  with  levels  returning  to 
baseline  prior  to  day  4  (i.e.  next  dose)  (168,  178-180).    Data  to  indicate  drug 
effects in tumour and BM tissue are conflicting. In a murine model of MM the levels 
of proteasome inhibition achieved in the tumour was approximately half that of the 
blood (176), however data from a phase I trial in prostate cancer showed levels in 
blood and tumour were equivalent. Proteasome inhibition achieved in the BM was 
assessed in 2 patients in this trial and the levels were approximately half that seen 
in the blood (173).  
 
1.10 The proteasome in CML 
There is evidence that the proteasome may provide a relevant therapeutic target in 
CML.  BCR-ABL+  cells  have  significantly  higher  levels  of  proteasome  activity 
relative to comparable BCR-ABL- cells (as measured by turnover of fluorescent 
substrate for CT-L activity).  Furthermore, relatively high activity in 6 diagnostic BM 
samples from patients with CML has been demonstrated (2). This is consistent 
with data from other malignancies.  
 
1.10.1 Published use of proteasome inhibitors in CML 
A  number  of  in  vitro  studies  of  PI,  including  bortezomib,  in  CML  have  been 
published. These will  be reviewed in detail in the Discussion chapter. Despite 
promising in vitro effects, there is little in vivo data.  A phase 2 study has been 
published in abstract form, where bortezomib was used as monotherapy in 7 IM-
refractory  or intolerant  patients.  Data  suggest in vitro  and  in vivo  effects  from 
analysis of apoptosis of patient derived mononuclear cell samples. No cytogenetic 
responses were seen and no survival data were presented (181).  
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1.11 Rationale for this study 
There is promising published data and a logical rationale for the use of PI in CML.  
Targeting the proteasome may offer a solution to the two key problems with TKI 
therapy: that of IM resistance, commonly in the form of BCR-ABL mutations; and 
the  relative  insensitivity  of  the  stem  cell  to  TKI.  Cell  line  studies  have 
demonstrated  that  IM-resistant  cells  are  susceptible  to  bortezomib  (1)  though 
particular effects on viability and proteasome activity in cells with specific BCR-
ABL+ mutations have not been presented. Little work has been published on the 
effects of bortezomib on the Ph+HSC though 2 groups have published CFU data 
(3,  8).  Assays  that  have  demonstrated  TKI  effects  on  the  quiescent  Ph+HSC 
population  include  CFSE  tracking  of  cell  division  and  FACS  to  obtain  the 
CD34+38-  population.  This  has  not  investigated  in  CML  with  bortezomib.  The 
current  clinical  trial  profile  of  bortezomib  serves  to  demonstrate  that  PI  are 
effective agents  in combination  with  established therapies. There is  preliminary 
published data with conflicting results in BCR-ABL+ cell lines with bortezomib in 
combination with IM (1, 155). Dasatinib is a more potent TKI than IM though has 
not been assessed in combination with bortezomib. Combination of these agents 
would  establish  whether  potent  inhibition  of  BCR-ABL  and  proteasome  activity 
could result in synergistic effects on cell viability. This may be particularly relevant 
in the Ph+HSC as BCR-ABL activity has been shown to be relatively high in this 
population (4). These questions provide the basis of the novel work performed in 
this project which aims to enhance knowledge in this field and may provide the 
basis for a clinical trial.  
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1.12 Stated hypotheses and aims 
 
The hypothesis as stated in the grant proposal:  
 
“Increased  BCR-ABL  expression  in  CML  stem  cells  may  lead  to  increased 
proteasome activity, therefore, simultaneous inhibition of both BCR-ABL tyrosine 
kinase and proteasome activity might induce CML stem cell specific apoptosis and 
this combined treatment could be clinically translated in the immediate future.” 
 
The individual aims are stated as follows: 
 
1  Effect of PI on viability and proliferation in BCR-ABL+ cell lines including 
those resistant to TKI 
2  Proteasome activity in BCR-ABL+ cell lines 
3  Effect of PI on BCR-ABL activity in BCR-ABL+ cell lines 
4   Effect of PI on viability and proliferation of CML patient samples 
5  Effect of PI on BCR-ABL activity in CML patient samples 
6  Proteasome activity of CML patient samples 
7  Effect of PI on primitive cells from CML patient samples 
8  Effect of PI on non-CML patient samples  
9  The potential synergistic effect of PI and TKI on viability and proliferation of 
BCR-ABL+ cell lines and CML patient samples. 
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2. METHODS 
 
2.1 Reagents and Equipment 
 
2.1.1 Reagents 
 
Reagent  Company and address 
2-mercaptoethanol  Invitrogen, UK 
7-amino-actinomycin D (7-AAD, Via-Probe
TM 
solution) 
BD Biosciences 
Adenosine triphosphate (ATP)  Sigma-Aldrich, UK 
Annexin V-FITC  BD Biosciences 
Beta-mercaptoethanol  Sigma-Aldrich, UK 
Bortezomib  Janssen-Cilag International 
NV, Beerse, Belgium 
Bovine Serum Albumin/Insulin/Transferrin 
(BIT) 9500 
StemCell Technologies Inc., 
USA 
BSA
TM Protein Assay Kit  Pierce, Rockford, USA 
Carboxy-fluorescein diacetate succinimidyl
 
diester (CFSE)  
Invitrogen, UK 
Dasatinib  Bristol-Myers Squibb, 
Princeton, USA 
Demecolcine (Colcemid®, N-Deacetyl-N-
methylcolchicine) 
Sigma-Aldrich, UK 
Dimethyl sulphoxide (DMSO)  Sigma-Aldrich, UK 
Dithiothreitol (DTT)  Sigma-Aldrich, UK 
DNase I  StemCell Technologies Inc., 
USA 
Dulbecco’s Phosphate Buffered Saline (D-
PBS) 
Sigma-Aldrich, UK 
ECL+
TM Chemiluminescence solution  GE Healthcare UK Ltd. 
FACSFlow
TM  BD Biosciences, San Jose, 
CA 
Fetal calf serum (FCS)  Invitrogen, UK 
FIX and PERM kit  Caltag laboratories, 
Burlingame, CA 
Full range Rainbow® recombinant protein  Amersham Biosciences,   52 
molecular weight marker (12-225x10
3Mr)  Buckinghamshire, UK 
Granulocyte-Colony Stimulating Factor  Chugai Pharma Europe, UK 
Human Serum Albumin 20%  Scottish National Blood 
Transfusion Service 
Imatinib  Novartis Pharma, Basel, 
Switzerland 
Isove’s modified Dulbecco’s media (IMDM)  Sigma-Aldrich, UK 
Laemmli sample buffer  Bio-Rad Laboratories, 
Hercules, CA 
L-Glutamine  Invitrogen, UK 
Low density lipoprotein  Sigma-Aldrich, UK 
Magnesium Chloride  Sigma-Aldrich, UK 
MG132  Calbiochem®, Merck, 
Darmstadt, Germany 
MgCl2  Sigma-Aldrich, UK 
Non-fat dried milk  Morrisons supermarket, UK 
Nonidet® P-40  Roche Diagnostics, 
Mannheim, Germany 
PE-conjugated rabbit anti-active caspase-3.  BD Biosciences 
Penicillin/Streptomycin  Invitrogen, UK 
Propidium iodide  BD Biosciences 
Re-Blot
TM Plus Antibody Stripping Solution 
 
Upstate, Temecula, USA 
Recombinant human Flt-3 ligand  StemCell Technologies Inc., 
USA 
Recombinant human IL-3  StemCell Technologies Inc., 
USA 
Recombinant human IL-6  StemCell Technologies Inc., 
USA 
Recombinant human Stem Cell Factor  StemCell Technologies Inc., 
USA 
Recombinant murine IL-3  Peprotech, NJ, USA 
RPMI-1640 media  Sigma-Aldrich, UK 
10xTG buffer 
Tris (25mM pH 8.3)/Glycine (192mM) 
Bio-Rad Laboratories Ltd., UK 
10xTGS buffer 
Tris (100mM pH8.3)/Glycine (100mM)/SDS 
(0.1%)  
Bio-Rad Laboratories Ltd., UK   53 
Tris-HCl  Sigma-Aldrich, UK 
Trisodium citrate  Sigma-Aldrich, UK 
Trypan blue  Sigma-Aldrich, UK 
Tween®-20 (polyethylene glycol sorbitan 
monolaurate) 
Sigma 
Z-ARR-AMC  Calbiochem 
Z-LLE-AMC  Calbiochem 
Z-Succ-LLVY-AMC  Calbiochem 
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2.1.2 Equipment 
 
Equipment  Use  Company 
Branson 200 Ultrasonic 
cleaner 
Sonication of 
proteasome activity 
lysates 
Kell-Strom, 
Wethersfield, USA 
Cimarec® hot plate  Adhesion of MeltiLex® 
and FIltermat A prior to 
scintillation counting 
Barnstead International, 
Thermo Fisher 
Scientific, Iowa USA 
Criterion® Blotter Filter 
paper 
Western blot  Bio-Rad Laboratories 
Ltd., UK 
Epson Perfection 4490 
Photo Scanner 
Western blot  Epson UK Ltd. 
FACSAria   Cell sorting 
FACSCaliber  Flow cytometry 
BD Biosciences, San 
Jose, CA 
Gilson Pipetman Single 
channel Pipettes 
Pipetting  Gilson, Inc., Middleton, 
USA 
Haemocytometer  Cell counting  Hawksey, UK 
Kodak X-OMAT 1000  Development of 
photographic film 
Carestream Health Inc., 
Rochester, NY, USA 
MicroBeta FilterMate-96 
Harvester 
Cell harvesting prior to 
analysis with scintillation 
counter 
MicroBeta Trilux beta-
scintillation counter 
Cell line proliferation 
PerkinElmer Life and 
Analytical Sciences, 
Milano, Italy 
Mini-PROTEAN® 3 cell  SDS-PAGE  Bio-Rad Laboratories 
Ltd., UK 
Multiscan EX 
photometer 
Protein concentration 
estimation 
Thermo Fisher Scientific 
Nitrocellulose 
membrane 
Western blot  Bio-Rad Laboratories 
Ltd., UK 
PowerPac300  Electrophoresis and 
Semi-dry transfer in 
Western blot 
Bio-Rad Laboratories 
Ltd., UK 
Spectramax M5  Proteasome Activity 
Assay 
Molecular Devices 
Thermoshaker  95C incubation in 
Western blot 
Schutron, Reutlingen, 
Germany 
Trans-Blot® SD Cell  Semi-dry transfer in 
Western blot 
Bio-Rad Laboratories 
Ltd., UK 
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2.1.3 Antibodies for Western blotting and Flow Cytometry 
 
Antibody  Use  Company 
Anti poly (ADP-ribose) 
polymerase (PARP), 
(rabbit) 
Western blot  Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti active caspase-3  Flow cytometry  BD Biosciences, San 
Jose, CA 
Anti rabbit IgG, HRP-
linked 
Western blot  Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti mouse IgG, HRP-
linked 
Western blot  Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti ubiquitin (P4D1) 
(mouse) 
Western blot  Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti phosphorylated Crkl 
(rabbit) 
Western blot  Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti p27
kip1 (rabbit)  Western blot  Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti pan-actin (rabbit)  Western blot  Cell Signaling 
Technology, Inc. 
Danvers, USA 
Anti CD34-APC  Flow cytometry  BD Biosciences, San 
Jose, CA 
Anti CD38-FITC  Flow cytometry  BD Biosciences, San 
Jose, CA 
Annexin V-FITC  Flow cytometry  BD Biosciences, San 
Jose, CA 
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2.2 Drugs 
The drugs were stored as aliquots as follows: dasatinib as 10mg/mL (2.05mM - 
based  on  molecular  weight  488.01)  in  dimethyl  sulphoxide  (DMSO)  at  -20˚C; 
imatinib  mesylate  as  59mg/mL  (100mM  based  on  molecular  weight  589.7)  in 
sterile  distilled  water  at 4˚C;  MG132 as  48mg/mL (100mM  based on molecular 
weight 475.6) in sterile D-PBS at -20˚C; and bortezomib as 1mg/mL (2.6mM based 
on molecular weight 384.24) in sterile 0.9%NaCl at -20˚C. 
 
2.3 Cell lines and patient samples 
 
2.3.1 Cell lines 
Three cell lines were used. K562 cells are a BCR-ABL+ immortilised human cell 
line  derived  from  a  patient  with  BC  CML  (182,  183).  HL60  are  a  human 
promyelocytic leukaemia cell line (BCR-ABL-). Ba/F3 cells are a mouse pro-B cell 
line.  Wild-type  (WT)  Ba/F3  are  BCR-ABL-  and  dependent  on  IL-3  for  growth. 
Ba/F3 cells transfected with BCR-ABL (BCR-ABL+ Ba/F3) grow independently of 
IL-3.  Used here were Ba/F3 transfected with p210 (unmutated, Ba/F3-p210) or 
with mutated BCR-ABL (BaF/3-T315I, Ba/F3-H396P and BaF3-M351T).  
 
All cells were cultured in suspension (humidified incubator at 37˚C and 5%CO2) in 
RPMI-1640 media supplemented as shown (RPMI-1640 cell culture media 2.8.1).  
WT-Ba/F3 required addition of IL-3 at 10ng/mL. All cells were counted every 2-3 
days  and  resuspended  in  fresh  media  at  a  concentration  of  approximately 
2x10
5cells/mL. 
 
2.3.2 Patient samples 
Patient samples were leukapheresis products taken at time of diagnosis with CP 
CML,  with  informed  consent  and  approval  of  the  NHS  Greater  Glasgow 
Institutional Review Board. The CD34+ population was enriched using CliniMACS 
(Miltenyi Biotech, Auburn, CA) according to standard protocols, prior to storage as 
aliquots at -150ºC. For particular experiments CML CD34+ samples were stained 
with  CD34-APC  and  CD38-FITC  and  sorted  using  a  FACSAria  to  obtain  the 
CD34+38- population, which represent primitive HSC.  
 
Prior  to  use,  patient  samples  were  rehydrated  in  10mL  DAMP  solution  (2.8.2 
incubated at 37ºC prior to use) added drop-wise to the cell solution.  The solution   57 
was washed in DAMP solution three times (1000rpm for 10 minutes). Following 
the third wash the pellet was suspended in 10mL of serum free medium (SFM 
2.8.3) with a 5 growth factor cocktail (+5GF 2.8.4) in a 25mL tissue culture flask.  
SFM+5GF was used for all CML and non-CML samples except where stated SFM-
5GF.  The cells were maintained overnight in a humidified incubator at 37ºC and 
5%  CO2.    The  cells  were  counted  and  assessed  for  viability  by  trypan  blue 
exclusion prior to use.   
 
2.4 Viability and apoptosis assays 
 
2.4.1 Assessment of viable cell counts 
Cells were counted by vital dye exclusion. An equal volume of a 0.8mM Trypan 
blue solution was added to an aliquot of the sample under investigation. The cell 
count was then performed by light-microscopy using a haemocytometer under x40 
magnification. The viable cell count was the number of cells which had maintained 
membrane  integrity  with  exclusion  of  dye.  All  counts  were  performed  as  a 
minimum in duplicate. 
 
2.4.2 Apoptosis assays using flow cytometry 
Cells were assessed for the presence of early and late apoptosis using annexin V-
FITC and 7-amino-actinomycin D (7-AAD). One of the early changes of apoptosis 
is the translocation of phosphatidyl serine from the inner to outer cell membrane 
leaflet.  As  a  consequence  of  this  translocation  phosphatidyl  serine  is  then 
available  for  binding  by  Annexin-V.  Cells  will  continue  to  bind  Annexin-V  even 
once membrane integrity is breached and the cell has died.  The vital dye 7-AAD 
will only bind cells where the membrane integrity is lost (as with Trypan blue and 
propidium  iodide,  PIo).    7-AAD  was  used  in  conjunction  with  Annexin-V  to 
distinguish cells in early and late apoptosis (Annexin-V+ 7-AAD- versus Annexin-
V+ 7-AAD+) (Figure 2.1).  
 
Cells were cultured in appropriate media and exposed to drug prior to analysis at 
the stated times.  For the drug wash-out experiments, cells were cultured in drug-
containing media which was replaced with drug-free media (two washes in D-PBS 
with a 5 minute 1200rpm spin) at stated times with all aliquots analysed at 72h.  
For  the  apoptosis  assay,  samples  were  spun  (1200rpm  for  5  minutes)  then 
resuspended in 100µL binding buffer (10mM Hepes/NaOH (pH7.4), 140mM NaCl,   58 
2.5mM  CaCl2)  and  incubated  in  the  dark,  at  room  temperature,  with  the 
fluorescent-labelled antibody for 15 minutes (5 L annexin-V and 10 L Via-Probe 
solution/1x10
5cells). 400µL of binding buffer was added to each sample and then 
analysed  immediately.    The  use  of  non-viable,  unlabelled  and  single-labelled 
controls provided appropriate compensation between channels prior to analysis of 
the experimental arms.  Annexin-V was labelled with FITC and so analysed in FL1, 
7-AAD was detected in FL3. The viable cell count was derived from the cell count 
by  trypan  blue  exclusion  and  light  microscopy.  It  was  assumed  that  this  count 
represented the total 7-AAD negative population (by flow cytometry). The ratio of 
cells  staining  both  negative  for  annexin-V  and  7-AAD  compared  to  all  7-AAD 
negative cells could then be applied to the trypan blue cell count (assumed equal 
to  all  7-AAD  negative  cells)  to  get  a  more  accurate  “viable  cell  count  by  flow 
cytometry”  which  would  then  take  account  of  cells  in  early  apoptosis.  The 
percentage of cells in early and late apoptosis was used to give a total percentage 
apoptosis.   
 
Figure  2.1  Determination  of  cells  undergoing  apoptosis  by  flow  cytometry  with 
Annexin-V and 7-AAD staining 
 
2.4.3 Intracellular caspase staining 
A key regulator activated during the early stages of apoptosis is caspase-3. The 
presence of this enzyme is an accepted marker for cells undergoing apoptosis. 
The mAb recognises the active form in human and mouse cells. Here we used a 
monoclonal rabbit antibody (mAb) conjugated to PE which recognises the active 
form of caspase-3 in mouse and human cells.  
 
This technique required flow cytometry to assess binding of the labelled antibody 
to intracellular antigens and was performed using the FIX and PERM kit. Cells   59 
were spun (1200rpm for 5 mins) and the pellet resuspended in 100µL of Reagant 
A  (a  formaldehyde-containing  commercial  solution  for  cell  fixation)  and  then 
incubated at room temperature for 15 mins.  The cells were then washed in D-PBS 
as  before  and  the pellet resuspended  in 100µL  of  Reagant B (commercial cell 
permeabilisation  solution).    10µL  of  PE-labelled  anti-caspase-3  antibody  was 
added and the samples incubated in the dark for 60 mins. Prior to flow cytometry 
the samples were washed twice in D-PBS (each spin 1200rpm for 5 mins). For 
each  experiment  an  unstained  and  isotype  control  was  used  to  set  analysis 
parameters.  
 
2.4.4 Thymidine proliferation assay 
This assay was to assess proliferation of cell lines in the presence of drug.  It was 
assumed  that  incorporation  of 
3H-thymidine  was  proportional  to  the  rate  of 
proliferation at the time of analysis. Cells seeded at 2.5x10
5/mL in a 96-well plate 
and  exposed  to  relevant  concentrations  of  drug.  On  the  day  of  analysis  a 
0.2 Ci/mL solution of 
3H-Thymidine in RPMI-1640 cell culture media was added to 
each  sample.  Following  4h  incubation  cells  were  harvested  onto  a  printed 
glassfibre filtermat (Filtermat A), which was then sealed with a melt-on scintillator 
sheet (MeltiLex® A) at 95° C and placed in a sample  bag prior to analysis with a 
beta-scintillation  counter.  Each  experiment  was  performed  as  a  minimum  in 
triplicate. 
 
2.4.5 CFSE staining  
 
2.4.5.1 Background  
This technique has an established role in tracking cells as they undergo division 
(184) and was applied to total CD34+ patient samples to assess the effects of drug 
treatment. CFSE crosses freely into cells where endogenous esterases remove 
acetate groups rendering CFSE membrane-impermeable and highly fluorescent. 
In addition, the succinimidyl group forms stable covalent bonds with intracellular 
proteins.  In  effect  the  molecule  is  “trapped”  within  the  cell  and  divided  equally 
between  daughter  cells  with  each  cell  division.  This  stepwise  reduction  in  cell 
fluorescence was visualised by flow cytometry (FL1 channel) enabling estimation 
of  the  number  of  divisions  a  sample  of  cells  has  undergone.  The  protocol 
described here was adhered to. 
   60 
2.4.5.2 Day 0  
CD34+  CML  patient  samples  were  taken  from  liquid  nitrogen  storage  and 
rehydrated by drop-wise addition over 10mins of 10mL of an ice-cold solution of 
2% FCS in D-PBS (FCS/PBS). The cells were then washed twice (1000rpm for 
10mins) in 10mL 2% FCS/PBS, resuspended in 5mL of 2% FCS/PBS, transferred 
to  a  sterile  50mL  tube  and  counted  by  dye  exclusion  (as  described  above).  2 
aliquots of 0.5x10
6cells were removed and made up to 1mL (for day 1 analysis) 
and 2mL (day 3 analysis) with SFM+5GF (CFSE-). The remaining cell solution was 
made up to 5mL with 2% FCS/PBS. CFSE (stored as aliquots of 5mM in DMSO at 
-20ºC) was added to this sample to give a final concentration of 1µM. Once CFSE 
was added the sample (CFSE+) underwent 10mins timed incubation in a water 
bath at 37ºC. 50mL of ice-cold 20% FCS/PBS (quenching solution) was added and 
the cells spun and then washed in 2% FCS/PBS (both 1000rpm for 10mins). The 
cells were then resuspended in 10mL of SFM+5GF in a 25mL sterile flask. CFSE+ 
and CFSE- samples were incubated overnight at 37° C  and 5% CO2. 
 
2.4.5.3 Day 1  
Sufficient SFM+5GF was added to the CFSE+ cells to give a final concentration 
2.5x10
5cells/mL. 500µL samples were added to a 48-well plate and exposed to the 
relevant  experimental  conditions.  For  each  experiment  2  samples  were  treated 
with 100ng/mL demecolcine (Colcemid®, stored as a 25ng/mL stock solution at 
4ºC).  Demecolcine  arrests  the  cell  cycle  in  metaphase  by  depolymerising 
microtubles and was used to determine the position of the undivided population by 
flow  cytometry  at  day  3.  In  addition,  3  unstained  and  3  CFSE-stained  controls 
were used. All experimental samples were incubated for 72h at 37° C and 5% CO 2.  
 
2.4.5.4 Day 3   
Each  sample  was  well  mixed  and  a  cell  count  performed.  The  samples  were 
transferred to a FACS tube with an additional rinse of each well (2% FCS/PBS) to 
minimise wastage. The cells were spun (1200rpm for 5mins) and the supernatant 
discarded. To determine CD34+ cells, 5 L CD34-PE antibody was added to each 
pellet  (excluding  controls)  the  samples  mixed  and  left  at  room-temperature  for 
15mins. The samples were then washed twice with 2% FCS/PBS (1200rpm for 
5mins). To determine viable cells, 2 L propidium iodide (PIo) in 2mL 2% FCS/PBS 
was  added  to  each  sample  (excluding  controls).  Viable  cell  membranes  are 
impermeable to PIo however this dye will bind the DNA of on viable cells with   61 
disrupted membranes and once bound displays enhanced fluorescence. The were 
cells  then  spun  (1200rpm  for  5mins),  the  supernatant  discarded  to  remove 
unbound PIo  and  the pellet resuspended in a small volume of FACSFlow
TM (a 
commercial  PBS/azide  solution)  and  then  analysed  by  flow  cytometry.  The 
controls (CFSE+ with PIo, CFSE+ with PIo and CD34-PE, CFSE- with PIo and 
CFSE- with PIo and CD34-PE) enabled appropriate detection of the live cells on 
forward (FSC) and side-scatter (SSC) with adequate compensation between the 
channels FL1 (detecting CFSE), FL2 (PE) and FL3 (PIo). 
 
2.4.5.5 Calculation of cell numbers  
The number of viable cells was estimated by trypan blue cell count at days 0, 1 
and 3. At day 3 a gate was created on the forward and side-scatter plots to include 
cells and exclude cell debris. The focus of analysis was then limited further by 
gating only on viable (PIo-) and CD34+ cells. From this population, undivided cells 
were assumed to be those with CFSE fluorescence of an intensity comparable to 
the Colcemid® control (PIo-CD34+CFSE
MAX). A region was set around this peak 
to  include  all  cells  with  comparable  CFSE  staining.  Subsequent  division  peaks 
were set by calculating regions where the mean CFSE fluorescence intensity was 
approximate  half  that  of  the  preceding  region.  For  assessment  of  the  CD34+ 
percentage for each division peak only PIo- cells were included. For assessment 
of the percentage of cells in each division viable (PIo exclusion) cells both CD34+ 
and  CD34-  were  included.  Calculation  of  the  cell  recovery  was  a  method  for 
determining  how  many  of  the  seeding  population  of  cells  (presumed  to  be 
undivided) could be accounted for at day 3 – a formula was applied (Equation 2.1) 
where R=recovery number n0= number of undivided cells, n1=number of cells in 
division 1, n2=number of cells in division 2, n3=number of cells in division 3 and so 
on. 
 
      .....
4 3 2
3 2 1
0
n n n
n R + + + =     Equation 2.1   
 
The recovery number was then compared (as a percentage) to the known input 
number  to  calculate  a  recovery  percentage.  The  percentages  could  then  be 
compared to the no drug control arm. The day 3 recovery of viable undivided cells 
(CD34+PIo-CFSE
MAX) was also compared between the experimental arms.  
   62 
2.5 Western Blotting 
 
2.5.1 Estimation of protein concentration 
The BSA
TM Protein Assay Kit was used. This method exploited the colour change 
associated with the reduction of copper ions by protein in alkaline conditions. The 
colour change was detected as absorption at 550nm by photometer. Standards of 
known protein concentration were made from dilutions (5 g/mL to 1500 g/mL) of 
bovine serum albumin in water. These were loaded as duplicate 25 L samples in 
a 96-well plate. Aliquots of the sample under analysis were added, in duplicate, as 
a 1:5 dilution in water (5 L sample and 20 L water).  To each well was added 
200 L of a mixture of the alkaline BCA
TM Solution A (50 parts) and the copper-
containing BCA
TM Solution B (1 part). The plate was incubated for 30mins at 37° C 
and loaded on a photometer with light absorbance measured using a 550nm filter. 
The software (Ascent v2.6) plotted a derived linear-plot of protein-concentration to 
absorbance  and  provided  estimation  of  the  protein  concentration  of  the  diluted 
sample.  
 
2.5.2.1 Preparation of sample lysates  
Following 2 washes in ice-cold D-PBS (1200rpm for 5 mins), samples were re-
suspended in ice-cold 150 L lysis buffer (50mM Tris pH7.5, 150mM NaCl, 5mM 
EDTA, 1% Nonidet® P-40 substitute 2.8.5) containing a protease inhibitor cocktail 
(1 “Complete” Protease Inhibitor Cocktail tablet per 10mL lysis buffer).  Following 
10 minutes incubation on ice samples were spun (14000rpm for 10 minutes at 
4˚C)  and  the  supernatant  removed  for  analysis,  including  estimation  of  protein 
concentration as described above. Samples were stored at -80° C. 
 
2.5.2.2 SDS-PAGE electrophoresis  
10mcg of the protein lysate was made up to 10 L with H2O and mixed with an 
equal volume of loading buffer (2.8.6). The samples were incubated at 95° C for 5 
minutes, returned to ice then immediately loaded onto a 4-15% sodium dodecyl 
sulphate  gradient  gel  immersed  in  running  buffer  (2.8.7).  The  samples  were 
separated at 120V for 90mins using the Mini-PROTEAN® 3 cell system. For each 
gel a molecular weight Rainbow® marker sample was run.  
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2.5.2.3 Electrophoretic transfer  
A semi-dry transfer method was followed, using a Bio-Rad Trans-blot® SD cell. 
The gel “sandwich” was made as shown in Figure 2.2 and run at 10V for 30mins: 
 
 
Figure 2.2 Gel “sandwich” used for electrophoretic transfer 
 
The  nitrocellulose  membrane  and  filter  papers  were  soaked  in  transfer  buffer 
(2.8.8) prior to use. To prevent non-specific protein interactions with nitrocellulose, 
the membrane was incubated for 1h at room temperature with 5% milk in TBS-T 
(2.8.9/10) buffer (blocking solution). This and all subsequent washes and antibody 
incubations were performed with gentle agitation on a mixer platform 
 
2.5.2.4 Primary and secondary antibody incubation  
Following exposure to the blocking solution, which was discarded, the membrane 
was incubated overnight (4ºC) with the primary antibody of interest (1:1000 dilution 
in 10mL TBS-T with 1% milk). The following morning, the membrane was washed 
4 times with TBS-T. Each wash was 15mins on a mixer platform with sufficient 
buffer to completely cover the membrane. Membranes were then labelled with the 
appropriate horseradish peroxidase-labelled secondary antibody (1:3000 dilution 
in TBS-T with 1% milk) and incubated at room temperature for 1h.  After a further 
series of 4 washes of 15mins in TBS-T and a short incubation (2-5mins) with an 
ECL+
TM  chemiluminescence  solution,  the  images  were  developed  onto 
photographic film. The membranes were then stripped of bound antibody using 
Re-Blot
TM solution (15mins incubation at room temperature). Prior to probing with 
different primary antibodies the membrane was twice washed for 5mins with 5% 
milk in TBS-T. 
 
2x filter paper 
2x filter paper 
gel 
membrane 
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2.6 Proteasome extraction and activity assay 
This  followed  an  established  method  for  preparing  cell  lysates  with  preserved 
proteasome activity. The lysates were then incubated with individual fluorogenic 
substrates for each of the 3 enzymic activities of the proteasome. The release of 
the  fluorescent  substrate  was  detected  by  the  fluorimeter  and  enzymic  activity 
compared between different experimental conditions. 
 
Cells  (1x10
7)  were  washed in  D-PBS and  resuspended  in fresh  1mL  ATP/DTT 
lysis buffer.  After 10 minutes incubation on ice, the cells were sonicated and then 
spun  for 10 minutes at 13000rpm.  The supernatant  was collected and  protein 
concentration  calculated (as  described in 2.5.1). Samples  were  either  analysed 
immediately  or  mixed  with  20%  glycerol  and  stored  at  -80ºC.    The  fluorogenic 
substrates  N-Succ-LLVY-AMC,  Z-ARR-AMC  and  Z-LLE-AMC  (used  to  measure 
CT-L, T-L and PGH-L activities respectively) were stored protected from light, at -
20ºC as 10mM stock solutions in DMSO. The assay was carried out in ATP/DTT 
lysis buffer (2.8.11) containing 50µg of the protein extract, 5mM EDTA and 50µM 
fluorogenic  substrate  in  an  opaque-walled  96-well  plate.  Analysis  by  a  dual-
monochromator, multi-detection microplate reader immediately followed addition of 
the fluorescent substrate. Activity was represented by the release of fluorescent 
substrate  at  excitation  and  emission  wavelengths  of  380nm  and  460nm 
respectively  (manufacturer’s  recommendations).  Readings  were  taken  every 
5mins  for  35mins  and  expressed  as  arbitrary  fluorescence  units  (AFU).  The 
equation of the linear rise in AFU per unit time was used to determine the rate of 
fluorescence release (AFU/min). 
 
2.7 Software and Statistical Analysis 
 
2.7.1 Software used for data analysis 
GraphPad Prism® (version 4, California USA) was used to draw graphs, charts, 
calculate  descriptive  statistics,  predict  dose-response  curves  and  perform 
statistical analysis. The concentration of drug shown to achieve a 50% reduction in 
viable  cell  count  was  termed  LD50.  This  figure  was  estimated  from  the  dose 
response  curves  predicted  using  Prism®  software.  Flow  cytometry  data  was 
analysed  by  CellQuest  Pro  software  (BD  Bioscience).  Fluorimetry  data  was 
analysed by both SpectraMax® Pro 5 (derivation of numerical data) and Microsoft 
Excel® software (analysis of numerical data).   65 
2.7.2 Analysis of data from synergism experiments 
To assess synergism, dose-response data generated from drugs used individually 
and  in  combination  were  analysed  with  CalcuSyn®  (Version  2.0  Biosoft, 
Cambridge,  UK).  The  underlying  mathematical  model  is  described  in  detail  by 
Chou (185) and is outlined here. For this analysis a number of calculations were 
performed by the software (Equations 2.2-2.4). Prior to input of data, the viable 
cell  count  (as  a  percentage  of  untreated  control)  was  converted  to  an  effect 
(Equation 2.2) where fa is the fraction affected and VCC% the viable cell count 
expressed as a percentage of untreated cells.  
 
100
%
1
VCC
fa - =         Equation 2.2 
 
The  median-effect  equation  (equation  2.3)  forms  the  basis  of  the  Calcusyn® 
software analysis, where D was the dose of a drug, fa the fraction affected by D 
(percentage  inhibition/100),  fu  the  fraction  unaffected  (1-fa)  and  Dm  the  median 
effect dose (=LD50 as used here).  
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The logarithm of equation 2.3 formed the median-effect plot (equation 2.4) which 
converted the dose-effect curve to a straight line where m was the slope and Dm 
the anti-log of the x-intercept. 
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f
f
log log log - =     Equation 2.4 
 
The data was then assessed for conformity by generation of an r-value (where 
r>0.95  was  accepted).  For  the  combination  of  two  drugs  a  fixed  ratio  of 
concentrations was applied and this is illustrated in Figure 2.4.    66 
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Figure 2.3 Checker-square analysis of drug combinations. Drugs were analysed 
for effect individually (█) and then in combination at fixed ratios (█,█,█). It is this 
data that was analysed using Calcusyn®. The numbers shown indicate multiples 
of the drug concentration required to achieve a 50% effect. 
 
This data was then analysed within the software by equation 2.5 where (Dx)1 was 
the concentration of Drug 1 causing x% inhibition, (Dx)2 the concentration of Drug 2 
with x% inhibition and (D)1+(D)2  the concentration of Drug A and B with the same 
(x) degree of inhibition. 
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2
1
1
X X D
D
D
D
CI + =         Equation 2.5 
 
Therefore  a  ratio  is  derived  (Combination  Index,  CI)  where  >1  indicates 
antagonism,  <1  synergism  and  1  an  additive  effect.  The  degree  of  synergism 
corresponds to the CI as shown in Table 2.1. 
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Table 2.1 Assessment of synergism by combination index 
CI range  description  Graded symbols 
     
<0.1  Very strong synergism  +++++ 
0.-0.3  Strong synergism  ++++ 
0.3-0.7  synergism  +++ 
0.7-0.85  Moderate synergism  ++ 
0.85-0.9  Slight synergism  + 
0.9-1.1  Nearly additive  ± 
1.1-1.2  Slight antagonism  - 
1.2-1.45  Moderate antagonism  -- 
1.45-3.3  antagonism  --- 
3.3-10  Strong antagonism  ---- 
>10  Very strong antagonism  ----- 
     
Table adapted from Chou TC (185) 
 
Data  are  also  displayed  as  a  conventional  isobologram  (Figure  2.4)  where 
selected  linear  additive  effects  are  plotted  on  a  graph  of  (Drug  A,  Drug  B). 
Experimental  data  was  then  shown  and  compared  to  these  linear  plots  as 
synergistic (below the line), additive (on the line) or antagonistic (above the line).  
 
Figure 2.4 Illustration of isobologram. The broken line indicates additive effect (for 
example LD50) when considering two drugs (Drug A, Drug B). Experimental data 
may reveal ○ synergistic, x additive or ▲ antagonistic effects in combination. 
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2.8 Culture media and other stock solutions 
 
2.8.1 RPMI-1640 Cell Culture Medium for culture of cell lines 
  Final concentration 
Penicillin/Streptomycin  1x10
5units/L and 100mg/L 
Glutamine  2mM 
Foetal calf serum  10% 
Made up in 440mL RPMI 1640 
 
2.8.2 DAMP solution for rehydration of stem cells 
  Final Concentration 
DNase I  10000units/L 
Magnesium Chloride  2.5mM 
Trisodium citrate  16mM 
Human Serum Albumin 20%  1% 
Made up in 418.75mL D-PBS 
 
2.8.3 Serum Free Medium for culture of stem cells 
  Final concentration 
Bovine Serum Albumin/Insulin/ Transferrin 
(BIT9500) 
 
L-Glutamine  2mM 
Penicillin/Streptomycin  1x10
5units/L and 100mg/L 
2-Mercaptoethanol  0.1mM 
Low density lipoprotein  0.8µg/mL 
Made up in 97.25mL Isove’s modified Dulbecco’s media (IMDM) 
 
2.8.4 5-Growth Factor Cocktail used with SFM for stem cell culture 
  Final concentration 
IL-3  20ng/mL 
IL-6  20ng/mL 
Flt3  100ng/mL 
Stem cell factor  100ng/mL 
Granulocyte-Colony Stimulating Factor  20ng/mL 
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2.8.5 Protein lysis buffer for Western blot 
  Final concentration* 
Tris pH7.5  50mM 
Sodium chloride  150mM 
EDTA  5mM 
Nonidet® P-40 substitute  1% 
*Made in ddH20 
 
2.8.6 Loading buffer for Western blot 
  Volume per mL 
Laemmli sample buffer  950 L 
Β-mercaptoethanol  50 L 
 
2.8.7 Running buffer for Western blot 
  Volume per L 
10xTGS buffer  100mL 
ddH20  900mL 
 
2.8.8 Transfer buffer for Western blot 
  Volume per L 
10xTG buffer  100mL 
Methanol  200mL 
ddH20  700mL 
 
2.8.9 10xTBS buffer for Western blot 
  Final concentration* 
Tris-HCl, pH 8  0.1M 
NaCl  1.5M 
*Made in ddH20 
 
2.8.10 TBS-T Washing buffer for Western blot 
  Volume per L 
10xTBS  100mL 
ddH20  900mL 
Tween®-20  1mL   70 
 
2.8.11 ATP/DTT lysis buffer for proteasome activity assay 
  Final Concentration* 
Tris-HCl, pH7.8  10mM 
DTT†  0.5mM 
ATP†  5mM 
MgCl2  5mM 
*Made  in  ddH20  †Aliquots  of  DTT  and  ATP  were  stored  at  4ºC  and  -20ºC 
respectively and added immediately prior to use.   71 
3. RESULTS 
 
Aim 1 Effect  of  PI  on  viability  and  proliferation  in  BCR-ABL+  cell  lines 
including those resistant to TKI. 
 
The initial investigation of the effects of bortezomib exposure on BCR-ABL+ cells 
focussed on the proliferation and viability of cell line models for CML. Those used 
were K562 and BCR-ABL+Ba/F3 cells. K562 cells are an immortilised human cell 
line  derived  from  a  patient  with  CML  BC  and  are  an  established  model  for 
monitoring  drug  effects  (182).  Ba/F3  cells  are  murine,  IL-3  dependent 
haematopoietic  cells  which  may  be  reliably  transfected  with  BCR-ABL  thus 
rendering  their  growth  IL-3  independent.  BCR-ABL+  Ba/F3  cells  are  an 
established model for monitoring the effects of TKI (90). To achieve this aim it was 
also  considered  important  to  ensure  that  the  effects  of  the  drug  were  not 
influenced by the storage conditions used. 
 
3.1. Bortezomib is antiproliferative and induces apoptosis in BCR-ABL+ cell 
lines 
 
3.1.1 Cell counting and Flow cytometry 
BCR-ABL+ cell lines (K562 and Ba/F3-p210) were maintained in RPMI-1640 cell 
culture media and exposed to concentrations of bortezomib (1 to 40nM) for set 
time periods (24, 48 and 72h). For these initial experiments, dose-response curves 
for drug effect were established in K562 by cell counting at 24, 48 and 72h with 
vital  dye  exclusion.  The  cells  were  cultured  in  cell  culture  media  containing 
bortezomib added at the start of the experiment with no additional dosing or drug 
wash-out.  It  was  seen  that  an  increase  in  bortezomib  concentration  was 
associated with a decrease in viable cell count (Figure 3.1). Estimated LD50 for 
K562 were 6.4nM (24h) 5.6nM (48h) and 11.2nM (72h) (Table 3.1).    72 
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Figure 3.1. K562 cells were exposed to bortezomib for 24h (▬●), 48h (▬▲) and 
72h (▬▼) with the viable cell count expressed as a percentage of untreated cells. 
Points and error bars indicate mean±SEM and adjoining lines demonstrate dose-
response curves of best fit. 
 
K562  cells  were then examined  at 24,  48  and 72h of  bortezomib exposure  for 
early/late apoptosis by flow cytometry (as described in 2.4.2). It was shown that 
with  increasing  concentration  of  bortezomib  there  was  an  increase  in  the 
percentage of cells staining positive for annexin-V alone (early apoptosis) and both 
annexin-V and 7-AAD (late apoptosis).    73 
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Figure 3.2. (A) K562 cells were exposed to bortezomib and then analysed by flow 
cytometry to determine the total % cells undergoing apoptosis. Results from 24h 
(■)  48h  (■)  and  72h  (■)  drug  exposure  are  shown.  (B)  K562  cells  exposed  to 
bortezomib for 48h and analysed as in (A) then displayed to show the % cells in 
either  early  or  late  apoptosis.  Error  bars  indicate  mean±SEM.  Annexin-V  (An), 
detection/no detection of bound fluorophore by flow cytometry (+/-). 
 
A combination of vital dye exclusion and flow cytometry (as described in 2.4.2) 
was used to compare the effect of bortezomib on Ba/F3 p210 with Ba/F3 BCR-
ABL mutants (Ba/F3-M351T Ba/F3-H396P and Ba/F3-T315I) (Figure 3.3). LD50 
results  were  similar  between  the  4  BCR-ABL+  Ba/F3  transfectants  (Table  3.1) 
though there was a trend for the mutant forms to be slightly less sensitive than 
Ba/F3-p210.  
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Figure 3.3. BCR-ABL+ Ba/F3 cells were exposed to bortezomib for 24h and then 
analysed  by cell  counting and flow cytometry to  determine (A) the reduction in 
viable cell count (as a % of untreated cells) and (B) the increase in the % of cells 
in  early  and  late  apoptosis.  Points  and  error  bars  in  both  (A)  and  (B)  indicate 
mean±SEM  and  adjoining  lines  demonstrate  dose-response  curves  of  best  fit. 
Ba/F3-p210 (--■--) BaF3-M351T (--□--) Ba/F3-H396P (--◊--) Ba/F3-T315I (--○--).  
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Table 3.1. Estimation of bortezomib LD50 by cell counting and flow cytometry in 
BCR-ABL+ cell lines 
Cell type  Exposure time  LD50 (nM)  Figure 
K562  24h  6.4 
  48h  5.6 
  72h  11.2 
3.1 
Ba/F3-p210  6.3 
Ba/F3-H396P  10.8 
Ba/F3-M351T  11.3 
Ba/F3-T315I 
All 24h 
8.5 
3.3(A) 
 
3.1.2 Bortezomib stability 
It  is  the  recommendation  of  Janssen-Cilag  International  that  bortezomib  is 
administered  to  patients  immediately  following  reconstitution  in  sterile  9mg/mL 
NaCl for injection (bortezomib Summary of Product Characteristics August 2008). 
Independent  studies  have  shown  the  drug  to  be  stable  up  to  42d  after  once 
reconstituted in this way and stored at 4-5° C or room temperature (23° C) (186, 
187).  Here we used aliquots of reconstituted bortezomib stored initially at 4°C for 
<24h  and  then  as  aliquots  at  -20ºC.  Other  researchers  have  reconstituted  and 
stored bortezomib in a variety of ways. These include reconstitution and storage in 
DMSO (-20° C(1, 5, 9), -80°C (188) or no temperature  stated (123)), Me2SO (no 
temperature  stated),  PBS  (-20° C  (3)  or  no  temperatu re  stated)  (159,  161)  and 
9mg/mL  NaCl  (-70° C  (88)  or  no  temperature  stated  (8 )).  To  ensure  that  the 
method of storage that we adopted did not influence the drug effect we assessed 
the ability of fresh and stored bortezomib to induce cell death in K562 cells (Figure 
3.4). This experiment was performed only twice and so sufficient data to perform 
meaningful statistical analysis were not generated – however, it was considered 
that these data provided reassurance our storage method was appropriate and 
consistent with other workers in this field. 
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Figure  3.4.  An  investigation  of  the  effects  of  storage  and  freeze-thawing  of 
bortezomib  in  K562  cells.  Viable  cell  count  is  x10
4/mL.  Points  and  error  bars 
indicate  mean±SEM  with  adjoining  line  of  best  fit.  Conditions  compared  were 
bortezomib used within 24h of reconstitution (-■-), 24h storage at -20° C (- ◊-), 2m 
storage at -20° C (- ○-) and 3m storage at 4° C (- □-). 
 
3.1.3 Bortezomib wash-out 
Bortezomib  is  a  reversible  proteasome  inhibitor.  Data  generated  from  in  vivo 
exposure  indicates  that  peak  plasma  levels  may  be  acheived  in  the  PB  at  1h 
following administration with associated maximal proteasome inhibition (discussed 
in section 1.9.6). The exposure time required to achieve irreversible cell death may 
therefore be short. To investigate this drug wash-out experiments were performed 
with  K562  cells  as  described  in  2.4.2.  Cells  were  exposed  to  drug  containing 
medium for the stated times with the final analysis at 72h (Figure 3.5). The data 
show  that  in  our  in  vitro  system  between  12  and  24h  exposure  is  required  to 
induce significant cell death, hence a minimum of 24h exposure was used in our 
experiments. The limited effect of short exposure times may reflect the reversible 
nature  of  proteasome  inhibition  with  bortezomib.  In  addition,  drug  containing 
medium was incubated in cell culture conditions (37ºC with 5% CO2) for up to 72h 
prior to treatment of K562 cells. This caused no apparent reduction in efficacy for 
inducing cell death (data not shown here). This was interpreted as an indication 
that viable drug may be present in the cell culture media for up to 72h. However, 
metabolism of bortezomib by exposed K562 cells is not assessed by this method.   77 
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Figure 3.5. Effects of time limited exposure to bortezomib in K562 cells. All cells 
analysed by cell counting and flow cytometry at 72h after exposure to bortezomib 
containing media for set times from initiation of experiment. No wash out (-□-), 
wash out at 1h (-■-), 6h (-▲-), 24h (-▼-) and 48h (-●-) exposure. Viable cell count 
is x10
4cells/mL. Points indicate mean values for experiment with adjoining lines. 
 
3.1.4 Detection of active Caspase-3 
Active caspase-3 is a key regulator and a recognised marker of cells undergoing 
apoptosis. Cell viability experiments with annexin-V and 7-AAD staining provided 
an  indication  that  bortezomib  induced  apoptosis  in  BCR-ABL+  cell  lines. 
Demonstration of the presence of active caspase-3 was considered important to 
verify this by an alternative experimental technique. BCR-ABL+ Ba/F3 cells were 
treated with 20nM bortezomib for 24h, a viable cell count taken and then cells 
treated  as  described  in  2.4.3  to  determine  the  presence  of  active  caspase-3 
(Figure 3.6). For all BCR-ABL mutants a significant change in detectable active 
caspase-3  was  shown  when  compared  to  the  untreated  control  populations, 
though there was no statistically significant difference between the 4 transfectants 
in  either  viable  cell  count  or  %  of  cells  with  active  caspase-3.  These  findings 
confirm  that  bortezomib  induces  apoptosis  irrespective  of  BCR-ABL  mutation 
status and is consistent with published work in other cancer cell lines (3, 9, 148).   78 
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Figure  3.6.  Percentage  of  BCR-ABL+  Ba/F3  cells  with  active  caspases-3 
detectable by flow cytometry. A comparison is made between untreated cells (0) 
and  those exposed  to 20nM  bortezomib  (20) for 24h. There  was no significant 
difference (n.s.) between Ba/F3-p210 and the mutated BCR-ABL forms following 
drug exposure. 
 
3.1.5 Thymidine incorporation 
There is published data produced by various methods which show that bortezomib 
is antiproliferative in cancer cell lines (1, 6, 9). IM, dasatinib and nilotinib have a 
significant antiproliferative effect in BCR-ABL+ cells and this is likely to be relevant 
in  their  efficacy  for  treating  CML  a  disease  characterised  by  uncontrolled  cell 
proliferation. A method by which incorporation of 
3H-thymidine is measured was 
utilised  to  establish  whether  bortezomib  influenced  cell  proliferation.  K562  and 
BCR-ABL+ Ba/F3 cells were cultured with defined concentrations of bortezomib. It 
was seen that drug exposure was associated with reduced incorporation of 
3H-
thymidine, consistent with reduced proliferation when compared to the untreated 
cells.  Using  this  method  (2.4.4)  and  at  48h  drug  exposure  the  concentration 
required to inhibit proliferation by 50% in comparison to untreated cells (IC50) was 
estimated  at  8.4nM  (K562)  and  8.7nM  (Ba/F3-M351T).  As  a  consequence  of 
technical  problems  with  the  cell  harvester  this  assay  became  increasingly 
unreliable during the course of the project and so was used only in the preliminary 
experiments.   79 
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Figure 3.7. A reduction in proliferation with K562 cells (  X  ) and Ba/F3–M351T (--
○--)  cells  exposed  to  bortezomib  for  48h  as  measured  by  incorporation  of 
3H-
thymidine. Points and error bars indicate mean±SEM with line of best fit.  
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Aim 2 Proteasome activity in BCR-ABL+ cell lines 
 
It  has  been  demonstrated  that  cancer  cells  have  abnormally  high  levels  of 
proteasome expression and activity (133). Furthermore, there is evidence from cell 
line work and samples from patients with CML that the presence of BCR-ABL is 
associated with increased proteasome activity, as measured using a fluorescent 
substrate  based  assay  (2).  We  aimed  to  demonstrate  detectable  proteasome 
activity  in  the  BCR-ABL+  cell  lines  which  are  susceptible  to  the  apoptotic  and 
antiproliferative effects of bortezomib and to assess the impact on this activity of 
exposure to PI. 
 
3.2 Proteasome activity is detectable in BCR-ABL+ cell lines and in Ba/F3 
cells, is variable between different BCR-ABL mutations and is inhibited by 
bortezomib.  
 
3.2.1 Baseline proteasome activity in Ba/F3 mutants 
A fluorescence based assay (2.6) was used to measure the proteasome activity of 
Ba/F3  cells.  A  linear  rise  in  AFU  was  seen,  consistent  with  AMC  release 
representing  proteasome  subunit  enzyme  activity  (Figure  3.8  and  3.9). 
Interestingly, the basal proteasome activity appeared to vary between the Ba/F3 
BCR-ABL+  mutants  when  considering  PG  and  CT-L  activity.  Statistical 
significance was achieved in PG activity (p<0.01 (H396P), p=0.013 (M351T)) and 
CT-L activity (p=0.047 (T315I), p=0.045 (H396P), p=0.038 (M351T)).  
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Figure 3.8 Detectable proteasome subunit activity in Ba/F3-p210 (■) and K562 (■) 
cells expressed in AFU/min (mean±SEM). PG (post-glutamyl hydrolyzing), CT-L 
(chymotrypsin-like) and T-L (trypsin-like) activities are represented.   81 
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Figure 3.9 Proteasome activity in Ba/F3-T315I (■), Ba/F3-H396P (■) and Ba/F3-
M351T  (■)  expressed  in  AFU/min  (mean±SEM)  as  a  ratio  compared  to  Ba/F3-
p210.  PG (post-glutamyl hydrolyzing), CT-L (chymotrypsin-like) and T-L (trypsin-
like) activities are represented. * indicates statistical significance. 
 
3.2.2 Effect of bortezomib treatment on proteasome subunit activity 
Ba/F3  cells  were  cultured  in  the  presence  of  20nM  bortezomib  for  24h  and 
proteasome subunit activity assessed (as described 3.2.1). This concentration was 
chosen  to  induce  significant  apoptosis  and  impair  proliferation.  The  effect  of 
bortezomib of the subunit activities in the different BCR-ABL+ Ba/F3 cell types was 
similar and so data from the 4 types was pooled and is shown in Figure 3.10. 
Significant  residual  proteasome  subunit  activity  remained  despite  significant 
effects on viability (figure 3.3). This has been seen by others in HeLa cells where 
high  concentrations  of  bortezomib  (500nM)  were  required  to  achieve  >90% 
inhibition of CT-L activity (189). Of interest is that bortezomib inhibited all 3 subunit 
activities,  despite  the  purported  CT-L  selectivity  of  this  drug.  These  results  we 
show  are in concordance  with published data with bortezomib treatment of cell 
lines (10-500nM) and using a similar technique reveals inhibition of T-L (10->90%) 
and PG (20-90%) activities(186, 189).    82 
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Figure 3.10 Effect of bortezomib 20nM on proteasome subunit activity in BCR-
ABL+  Ba/F3  cells.  Results  shown  represent  %  AFU/min  in  comparison  to 
untreated  cells  (of  same  cell  type).  Pooled  data  is  shown  from  Ba/F3-p210,  -
H396P, -M351T and -T315I cells and expressed as mean±SEM. 
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Aim 3 Effect of PI on BCR-ABL activity in BCR-ABL+ cell lines 
 
Bortezomib has antiproliferative and apoptotic effects in BCR-ABL+ cells and this 
activity  is  associated  with  a  reduction  in  proteasome  activity.  The  deregulated 
tyrosine kinase activity of BCR-ABL is associated with the malignant phenotype 
and characterised by increased proliferation and cell survival (described in section 
1.5).  The  effect  of  proteasome  inhibition  on  BCR-ABL  activity  is  therefore  of 
interest. There is also particular relevance to the later aim of establishing whether 
there is potential benefit in combining bortezomib with TKI. 
 
3.3 Bortezomib reduces BCR-ABL activity in BCR-ABL+ cell lines 
 
3.3.1 Effect of bortezomib treatment on BCR-ABL activity in K562 cells 
K562 cells were exposed to bortezomib (2.5 to 20nM) or dasatinib (150nM) for 24h 
and then lysates prepared for Western blot analysis (2.4.2). Following SDS-PAGE 
electrophoresis and electrophoretic transfer onto a nitrocellulose membrane, the 
samples were probed with anti-pCrkl and anti-pan-actin. Crkl is an adaptor protein 
which  plays  an  important  role  in  BCR-ABL  mediated  signal  transduction.  The 
detection of pCrkl is an established method for demonstrating BCR-ABL activity. 
Crkl  is  tyrosine  phosphorylated  by  BCR-ABL  (190)  and  this  phosphorylation 
correlates  well  with  the  level  of  BCR-ABL  expression  (191).  Furthermore,  the 
reduction  in  pCrkl  as  a  consequence  of  BCR-ABL  inhibition  has  been 
demonstrated with TKI therapy in CD34+ CML cells (192). By this technique we 
demonstrated that in K562 cells bortezomib exposure appeared to be associated 
with a decrease in BCR-ABL activity. BCR-ABL activity was effectively reduced 
with exposure to 150nM dasatinib for 24h for comparison (Figure 3.11).   84 
 
 
Figure 3.11. Treatment of K562 cells for 48h. Membrane probed with anti-pCrkl 
and anti-pan actin. Additional second band in lower membrane is due to residual 
anti-pCrkl binding as a consequence of inadequate membrane stripping of an avid 
antibody.  Dasatinib  150nM  (das)  in  comparison  to  stated  nM  concentrations  of 
bortezomib.  Densitometry  (expressed  as  %  of  ND  control  and  relative  to  actin 
loading) das 24% bortezomib 1nM 109% 2.5nM 81% 5nM 21% 10nM 22% 20nM 
20%. 
pCrkl 
pan-
actin 
ND    das      1     2.5      5       10      20 
    Bortezomib (nM)   85 
Aim 4 Effect  of  PI  on  viability  and  proliferation  of  CML  patient  samples 
including the quiescent subpopulation 
 
Cell  line  work  established  that  bortezomib  was  antiproliferative  and  induced 
apoptosis in BCR-ABL+ cell lines with an associated decrease in BCR-ABL and 
proteasome  activity.  By  use  of  similar  techniques,  this  work  was  extended  to 
investigate  effects on BCR-ABL+  CD34+ cells taken  at  diagnosis  from  patients 
with CP CML.  
 
3.4  Bortezomib  is  antiproliferative  and  induces  apoptosis  in  CML  CD34+ 
patient samples  
 
CML CD34+ cells  were  cultured in SFM+5GF in the  presence and  absence of 
bortezomib. At each time point the viable cell count and percentage of apoptotic 
cells were calculated (as described 2.4.1 and 2.4.2). The effect of bortezomib did 
not  vary  significantly  between  different  patient  samples  as  is  seen  in  data 
generated from initial experiments (Figure 3.12A) and the results were therefore 
pooled with mean±SEM established and dose-response curves predicted (Figure 
3.12B).  The  LD50  was  8.8±0.7nM  (n=5)  at  24h,  7.6±0.4nM  (n=3)  at  48h  and 
5.7±1.6nM (n=7) at 72h. The effect of bortezomib on the expansion of the CML 
CD34+ cell population in SFM+5GF can be seen in Figure 3.12C.  
 
CML CD34+ (n=1) were also analysed for the effects of bortezomib on cell viability 
in SFM-5GF with the LD50 7.89±1.07nM (24h), 3.54±1.41 (48h) and 4.13±0.18nM 
(72h).  
 
 
Figure 3.12 (A) A comparison of the effect of 24h bortezomib exposure on the 
viable cell count of 3 different CD34+ CML patient samples cultured in SFM+5GF. 
CML217 (■), CML218 (■) and CML228 (□). Based on estimations from the curves 
of best fit the LD50 was 8.4nM (CML217), 9.2nM (CML218) and 10.4nM (CML228). 
(B) The effect of 24h bortezomib exposure on the viable cell count and % cells 
undergoing apoptosis in 5 different CD34+ CML samples cultured in SFM+5GF. □ 
viable cell count and ▲ % cells undergoing apoptosis with broken lines indicating 
predicted  curves  of  best  fit.  (C)  CD34+  CML  samples  (n=3)  were  seeded  at 
2.5x10
5cells/mL and then analysed for viable cell count and apoptosis at 24, 48 
and 72h. Points indicate untreated cells (-□-), 4nM, (-▲-), 8nM (-▼-) and 16nM (-
●-) bortezomib with adjoining lines. 
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      Figure 3.12 
 
Total CD34+ from 4 patients were taken and examined in duplicate on 3 separate 
occasions for the presence of intracellular active caspase-3 when cultured with 10 
and 20nM bortezomib. It was seen that there was a significantly reduced viable 
cell  count  in  all  these  3  samples  with  the  addition  of  bortezomib  at  these   87 
concentrations,  or  dasatinib  150nM.    There  was  a  trend  to  an  increase  in 
detectable  intracellular  activated  caspase-3  when  exposed  to  bortezomib 
(reaching  statistical  significance  with  20nM)  –  this  was  not  the  case  with  the 
dasatinib treated samples (Figure 3.13).  
 
A            B 
 
Figure 3.13. (A) Total CD34+ cells (n=4) cultured for 24h in SFM+5GF with viable 
cell  counts  taken  and  then  the  fold  increase  in  population  compared  between 
untreated cells (no drug) and those treated with bortezomib (10nM or 20nM) and 
dasatinib  150nM.  (B)These  samples  were  then  analysed  by  flow  cytometry  to 
assess the % cells with detectable active caspase-3. 
 
An important substrate of caspase-3 is poly(ADP-ribose) polymerase (PARP). This 
protein  plays  a  role  in  DNA  repair  and  is  cleaved  to  detectable  fragments  by 
caspases.  The  detection  of  these  fragments  is  therefore  a  useful  marker  for 
caspase activity and apoptosis. Here  we showed the cleavage of PARP in cell 
lysates following incubation of CML CD34+ cells for 24h with bortezomib (Figure 
3.14). The PARP antibody used detects full-length PARP (116kDa) and the large 
(89kDa) cleavage fragment. Dasatinib 150nM did not induce significant apoptosis 
at this time point.   88 
 
 
 
Figure 3.14. CML CD34+ cells treated with 10 or 20nM of bortezomib or 150nM 
dasatinib (das) and compared to untreated (ND) cells. All cells were cultured in 
SFM+5GF for  24h prior to  preparation  of cell  lysates for Western  blotting. The 
upper  band  represents  full  length  PARP  and  the  lower  the  89kDa  cleavage 
fragment. Membranes were probed with anti pan-actin to assess protein loading.  
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Aim 5 Effect of PI on BCR-ABL activity in CML patient samples 
Aim 6 Proteasome activity in CML patient samples 
 
These aims are considered together. Western blotting using a variety of different 
primary  antibody  incubations  enabled  both  questions  to  be  considered 
simultaneously in these experiments. 
 
3.5  Bortezomib  inhibits  proteasome  activity  but  does  not  affect  BCR-ABL 
activity in CML CD34+ patient samples 
 
The fluorescent substrate assay was not suitable for use in patient samples due to 
the large number of cells required (1x10
7) to provide the required 50-100µg lysate 
per  replicate.  Preliminary  experiments  using  fewer  K562  and  Ba/F3  cells  (0.1-
0.5x10
7cells)  were  unsuccessful  in  yielding  consistent,  detectable  proteasome 
activity. Therefore, indirect measures of proteasomal inhibition were investigated. 
Substrates are targeted for proteasomal degradation by the attachment of ubiquitin 
units  in  the  form  of  a  polyubiquitin  chain.  Therefore,  the  accumulation  of 
polyubiquitinated proteins, shown here by Western blot, is an accepted marker of 
proteasome inhibition. This method was applied to CML CD34+ cells following 24h 
exposure to bortezomib (Figure 3.15A). This effect was not seen with dasatinib 
150nM (Figure 3.16). We used the presence of the adaptor protein pCrkl as a 
specific marker of BCR-ABL kinase activity as described in 3.1.3. The detection of 
pCrkl  by  Western  blot  following  24  and  48h  bortezomib  and  24h  dasatinib 
treatment is seen in Figure 3.15B. Despite significant effects on cell viability there 
was minimal effect on BCR-ABL activity with either 10nM bortezomib (97±23%) or 
20nM bortezomib (73±5%) in contrast to dasatinib 150nM (23±10%) - results from 
24h drug exposure, expressed as densitometry readings (n=2) using the ratio of 
pCrkl:actin bands shown as a percentage of the untreated sample (mean±SD).  
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Figure 3.15 (A) Separate CML CD34+ samples (X, Y) were treated for 24h with 
bortezomib 10 or 20nM (10, 20) and compared with an untreated control (ND). 
Accumulation  of  poly-ubiquitinated  proteins  of  varying  molecular  weights  was 
seen. Protein loading was assessed using anti-actin antibody. Residual BCR-ABL 
activity  represented  by  the  pCrkl  band  can  be  seen  in  all  samples.  (B)  A 
representative CML CD34+ sample treated with bortezomib 10 or 20nM (10, 20) or 
dasatinib 150nM (das) for 24h and 48h and compared with untreated control (ND). 
The presence of the pCrkl band demonstrates the significant residual BCR-ABL 
kinase activity in PI treated samples compared with the abrogated activity in the 
das treated sample. 
 
 
The cyclin dependent kinase inhibitor p57
kip2 was also selected as a marker of 
proteasome  inhibition.  As  described  in  the  introduction,  the  CDKi  p27
kip1  and 
p57
kip2 are substrates for the proteasome and accumulation with PI exposure in 
cell lines has been demonstrated. We used an anti-p27
kip1 antibody which has dual 
specificity for p27
kip1 and p57
kip2. We failed to demonstrate  a clear band at the 
pan-actin 
pCrkl 
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24h  48h 
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expected molecular weight for p27
kip1 despite varying the quantity of lysate (10-
20µg  per  well)  and  by  use  of  a  15%  gel.  However  a  clear  band  was  seen 
consistent with the 57kDa protein p57
kip2 with relatively increased protein levels 
detected in those cells treated with 20nM bortezomib, consistent with proteasome 
inhibition (Figure 3.16). 
 
 
 
 
Figure 3.16 CML CD34+ cells cultured in SFM+5GF and treated with dasatinib 
150nM (das) or bortezomib at stated concentrations (2.5nM to 20nM) for 24h and 
compared with untreated cells (ND). Lysates were prepared for Western blot and 
membranes probed with anti-p27kip1, anti-ubiquitin and anti-pan-actin.  
p57
kip2 
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Aim 7 Effect of PI on primitive cells from CML patient samples 
Aim 8 Effect of PI on non-CML patient samples  
 
Patients with CML on TKI harbour a primitive population of cells, enriched within 
the CD34+38- fraction, which are resistant to TKI exposure. We aimed to establish 
whether these cells were sensitive to the effects of bortezomib and if so, whether 
there was any difference in sensitivity in comparison to a similar sub-population of 
cells derived from patients without CML. Proliferation assays using CFSE staining 
were  also  performed  to  achieve  Aim  7.  By  these  means  it  was  possible  to 
determine drug effects within distinct subpopulations separated by division number 
and therefore allowed assessment of the effect of bortezomib on quiescent cells. 
 
3.6 Bortezomib induces apoptosis in the CML CD34+38- population, though 
with minimal selectivity for leukaemic stem cells 
 
Previous work has demonstrated the relative insensitivity of early haematopoietic 
progenitor cells to TKI therapy. We used a process of cell sorting to isolate the 
CD34+38- fraction of the CD34+ CML patient samples. It is within this population 
that primitive progenitor cells are enriched as has been shown in both the normal 
marrow (37) and leukaemia (41, 42). CD34+38- cells were enriched from 3 CML 
CD34+ patient samples. Samples were cultured in SFM+5GF with bortezomib and 
viable cell counts taken at 24h of drug exposure (Figure 3.17A). Results  were 
compared  to  untreated  controls.  The  LD50  at  24h  was  8.93±1.42nM.  This  was 
similar to the LD50 of the unsorted CML CD34+ cells (section 3.4). To illustrate this 
consistent  effect  on  different  cell  populations,  CML  CD34+38-  and  CML 
CD34+38+ cells (n=3) were exposed to bortezomib for 24h and effects compared 
(Figure 3.17B). CD34+38+ enriched cells represent a relatively more mature and 
proliferating population of CML cells. LD50 values of 8.18±0.64nM for CD34+38+ 
cells  were  obtained  and  this  was  not  significantly  different  from  the  CD34+38- 
population.  
 
Similar experiments were performed in  duplicate using 2  non-CML samples. At 
24h drug exposure, the LD50 was 10.18±1.85nM (Figure 3.17C), which was not 
significantly higher than for CML CD34+38- cells. 
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Figure 3.17 (A) CD34+38- (n=3) cells were cultured in SFM+5GF and analysed at 
24h.  The  viable  cell  count  (□)  is  expressed  as  a  percentage  of  untreated  (cell 
count %). The percentage of cells staining positive for 7-AAD (▲) is expressed on 
the y–axis (% cells apoptotic). (B) The effect of bortezomib on CD34+38-(■) and 
CD34+38+ cells (□) (n=3) was compared. The viable cell count is expressed as in 
(A). (C) CD34+38- (n=2) cells from non-CML samples were cultured in SFM+5GF 
and  analysed  at  24h.  The  viable  cell  count  (□)  and  %  cells  apoptotic  (▲)  are 
derived as in (A). All results represent mean±SEM with predicted dose-response 
curves.  
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3.7 Bortezomib is antiproliferative in CML CD34+ patient cells 
 
The  effect  of  bortezomib  on  differentiation  and  division  of  CD34+  CML  patient 
samples  cultured  in  SFM+5GF  was  assessed  with  CFSE  and  flow  cytometry 
(2.4.5). A comparison of the effect of dasatinib 150nM or bortezomib 20nM with 
untreated  cells  is  shown  in  Figure  3.18A.  Here  3  control  groups  were  used: 
CFSE-,  showing  no  fluorescence  on  the  CFSE-channel  (FL1-H);  CFSE+  cells 
exposed to demecolcine to arrest cell division (undivided, CFSE
MAX); and CFSE+ 
cells exposed to no drug (untreated). In the analysis only viable cells (based on 
exclusion of PIo) were examined. For each sample a similar number of events 
(1x10
4)  from  each  sample  were  counted  therefore  cell  numbers  (“Counts”  in 
figures 3.18A and B) do not reflect the total number of residual viable cells for 
each condition. This data is examined in later figures. With 72h culture, untreated 
viable cells underwent up to 6 divisions, however cells exposed to greater than 
5nM of bortezomib underwent fewer divisions (Figure 3.18B). Exposure to 2.5nM 
bortezomib  over-lay  that  of  untreated  cells  (not  shown).  The  majority  of  cells 
exposed  to  20nM  bortezomib,  the  maximum  dose  used  in  these  experiments, 
failed to divide and the histogram (CFSE staining intensity, cell number) was seen 
to overlay the peak intensity of the demecolcine undivided control (Figure 3.18A 
and  B).  Consistent  with  published  data,  cells  exposed  to  150nM  dasatinib 
underwent fewer divisions when compared to the untreated controls (reference (4) 
and Figure 3.18A). Mean data generated from 2 different CD34+ CML samples 
were analysed in Figure 3.19 and demonstrate the percentage of viable cells in 
each division peak.   96 
A 
 
B 
 
Figure 3.18. Representative plots from CD34+ CML patient sample cultured for 
72h in SFM+5GF following CFSE exposure. (A) ▬ CFSE-, ▬ demecolcine, ▬ 
untreated,  ▬  dasatinib  150nM  and  ▬  bortezomib  20nM.  (B)  ▬  CFSE-,  ▬ 
demecolcine,  ▬  untreated,  ▬  bortezomib  5nM,  ▬  bortezomib  10nM  and  ▬ 
bortezomib 20nM. In (A) and (B) FL1-H (x-axis) indicates fluorescence intensity of 
CFSE  staining  and  Counts  (y-axis)  the  number  of  viable  cells  (based  on  PIo 
staining). The numbers above graph (A)  indicate number of cell divisions each 
population has progressed through. 
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Figure 3.19 CFSE stained cells cultured for 72h in SFM+5GF with no drug (█) 
dasatinib 150nM (█) or bortezomib 20nM (█). The percentage (not total number) 
of viable cells in each sample from each division peak is seen from undivided (0 – 
right) to 6 (left) divisions. Error bars indicate mean±SEM.  
 
The  number  of  cells  at  each  division  in  the  different  treatment  groups  was 
assessed as described in 2.4.5.4 with data shown in Table 3.2. Expansion of the 
CFSE+ cell population in SFM+5GF and the absence of drug was similar to that 
published  previously  (mean  3.77  versus  3.8  (60)).  The  percentage  recovery 
indicates that fewer cells were surviving in the bortezomib and dasatinib treated 
arms relative to untreated cells – though the percentage recovery considered low 
in the untreated arm, presumably a result of commitment to death in cells counted 
as viable at day 1. Of interest is that the apparent antiproliferative effect of both 
bortezomib 20nM and dasatinib 150nM results in relatively more viable quiescent 
cells  being  detected  in  the  sample  after  72h  culture  (Table  3.2).  The  effect  of 
bortezomib 10nM does not consistently produce this effect (Figure 3.20). 
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Table 3.2. CFSE data generated from 3 CML CD34+ samples analysed at 72h. 
Total CD34+ cells  undivided CD34+ cells  drug 
recovery 
(%) 
recovery 
relative to 
ND (%) 
viable cells  
(%) 
recovery of 
input (%) 
recovery 
relative to 
ND (%) 
           
ND  58.05  100  0.74  11.99  100 
B10  9.25  15.93  4.79  3.59  30 
B20  3.65  6.28  3.96  1.58  13.2 
DAS  29.69  51.15  3.05  18  150.1 
           
ND  33.05  100  0.83  3.32  100 
B5  26.39  79.5  1.35  4.3  115.1 
B10  11.08  33.52  7.66  3.82  110.2 
B20  11.94  36.14  44.35  3.66  290.4 
DAS  24.89  75.33  2.56  9.64  124.1 
           
ND  36.17  100  1.73  5.2  100 
B5  30  82.93  1.79  4.24  81.5 
B10  11.82  32.67  6.7  3.19  61.3 
B20  10.73  29.66  38.07  7.25  139.4 
DAS  15.19  41.99  4.25  3.19  61.3 
           
Results  from  3  different  samples  are  shown  CML232  (█),  CML194  (█)  and 
CML166 (█). All samples were cultured for 72h in SFM+5GF with (bortezomib (B) 
at  5,  10  or  20nM  or  dasatinib  (DAS)  150nM)  or  without  (ND)  drug  exposure. 
Recovery refers to a calculation based on the viable cell count and the percentage 
of cells in each division peak (from CFSE staining) which estimated the original 
number  of undivided  cells from which these  populations must have  arisen. For 
total CD34+ and undivided CD34+ (i.e. CFSE
MAX) a comparison was made to the 
untreated (ND) control (relative to ND columns). The percentage of viable cells 
which are undivided is also shown.    99 
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Figure 3.20. (A) Recovery of all CD34+ cells and (B) undivided (CFSE
MAX) CD34+ 
CML  cells  displayed  as  a  percentage  of  the  untreated  control  with  comparison 
between bortezomib 10nM and Dasatinib 150nM. For both graphs, CML194 (▲) 
CML166 (▼) and CML 232 (■). 
 
With evidence of cell division (by CFSE staining intensity) there was an associated 
reduction  in  the  percentage  of  CD34+  cells  consistent  with  the  loss  of  CD34 
expression associated with myeloid maturation (Figure 3.21). In dasatinib treated 
cells  there  was  a  trend  for  the  surviving  cells  at  each  division  peak  to  have 
relatively less CD34+ expression. This is in contrast to bortezomib treated cells 
where the opposite was seen. In the context of the results seen in Table 3.2 it 
appears  that  surviving  cells  have  undergone  fewer  divisions  and  are  of  a  less 
mature phenotype. This phenomenon has been noted by others using CD34+CML 
cells cultured in SFM-5GF (60).  
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Figure  3.21  CD34+  CML  samples  (n=2)  exposed  to  CFSE  and  cultured  in 
SFM+5GF for 72h. Division number represents the number of divisions each cell 
population  has  undergone  and  is  based  on  CFSE  staining  intensity,  %  cells 
CD34+  is  the  %  of  viable  CD34+  cells  (based  on  PI  staining)  of  that  CFSE 
intensity.  -■-  untreated,  -×-  dasatinib  150nM  and  -▼-  bortezomib  20nM.  Points 
indicate mean±SD with adjoining lines.   100 
Aim 9 The  potential  synergistic  effect  of  PI  and  TKI  on  viability  and 
proliferation of BCR-ABL+ cell lines and CML patient samples 
 
The current trend in the clinical use of bortezomib is for use in combination with 
other therapies. This is particularly appealing in the setting of this project as the 
results  of  Aim  8  indicate  toxicity  to  normal  cells.  Combination  therapies  are 
established  as  a  mechanism  of  increasing  toxicity  to  abnormal  cells,  through 
targeting  multiple  pathways  or  different  elements  of  similar  pathways  with  the 
associated benefit of potentially achieving similar effects with reduced individual 
drug exposure. We aimed to investigate the novel combination of bortezomib with 
a TKI. Dasatinib was selected as a model TKI due to the high levels of BCR-ABL 
inhibition that are recorded with clinically achievable doses. 
 
3.8 Dasatinib and bortezomib act synergistically against CML CD34+ cells  
 
Calcusyn® is a software package designed to estimate synergy between 2 drugs 
used together at a fixed ratio of concentrations. The sigmoidal dose-effect curve is 
converted through a logarithmic derivation to a linear graph (Equation 2.2 and 
2.3).  Data  derived  from  individual  drugs  can  then  be  compared  to  the  drug 
combination (which is considered as a 3
rd drug) by the CI (Equation 2.4) which is 
a measure of synergy/antagonism. 
 
CML CD34+ cells (n=3) were cultured in SFM+5GF and exposed simultaneously 
to a combination of bortezomib:dasatinib at different fixed ratios (2.5:1 to 10:1) . 
Cell counts and flow cytometry were performed at 72h to assess the effects on cell 
viability. This time point was chosen as preliminary experiments demonstrated that 
earlier time points underestimated cell death induced by dasatinib. The data were 
analysed  using  Calcusyn®.  Figure  3.22  illustrates  a  dose-effect  profile  of 
bortezomib, dasatinib and the drug combination (2.5:1).  
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Figure  3.22  Dose  effect  profile  for  dasatinib  (▬),  bortezomib  (▬)  and  2.5:1 
combination (▬). Effect (x-axis) is fa as calculated in Equation 2.3 and Dose (y-
axis) the concentration of drug (nM) and expressed as bortezomib concentration in 
the drug combination.  
 
This  data  may  also  be  viewed  as  an  isobologram  where  the  linear  profile  of 
defined effects (LD50, LD75 and LD90) is seen with the corresponding data from the 
drug combination experiments (Figure 3.23). Data fell consistently below the line 
of effect and so indicated synergy.   
 
 
Figure 3.23 Isobologram of fixed additive effects at LD50 (▬), LD75 (▬) and LD90 
(▬). Experimental data from ratio of 2:5:1 is shown corresponding to these effects 
(X, X and X) respectively.  
 
Synergy was demonstrated in these samples at both drug ratios and at end points 
including LD50, LD75 and LD90 (Table 3.3). 
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Table 3.3 Combination indices for bortezomib and dasatinib used simultaneously 
in CML patient samples. 
Combination index  Ratio 
LD50  LD75  LD90 
r-values 
         
2.5:1  0.67±0.16  0.54±0.16  0.53±0.21  0.85-0.99 
5:1  0.78±0.12  0.66±0.13  0.64±0.16  0.90-0.98 
10:1*  0.87±0.25  0.75±0.22  0.69±0.22  0.93-0.94 
         
Ratio described as bortezomib:dasatinib, synergism (█), moderate synergism (█) 
and slight synergism (█) as defined by Chou TC (185).  
*For 10:1 n=2, for 2.5:1 and 5:1 n=3.   103 
4. DISCUSSION 
 
4.1. Overview 
The current recommended treatment for the majority of patients with CP CML is 
IM. There is accumulating evidence that the majority of patients respond to this 
drug  and achieve the therapeutic milestone of a CCyR. However TKI induce a 
state of MRD and many patients continue to have detectable BCR-ABL transcripts. 
In addition, MRD may persist in those with undetectable BCR-ABL transcripts, with 
the “undetectable” results a reflection of the limitation of the assay rather than true 
CML eradication. There may be a subpopulation of patients treated with IM with 
undetectable BCR-ABL transcripts who have achieved disease eradication. This 
question was addressed in the Stop Imatinib (STIM) study, with preliminary results 
presented  recently.  Here  it  was  seen  that  15  of  34  patients  with  undetectable 
BCR-ABL  who  had  discontinued  IM  for  ≥6m  showed  no  evidence  of  disease 
relapse. Of these 5 patients had received IM therapy alone. However follow-up is 
relatively short and the recommendation remains that patients should be treated 
indefinitely (98).  
 
For the majority if IM treated patients, the source of MRD is presumed to be the 
population of Ph+HSC. These cells are relatively insensitive to TKI. Furthermore 
the development of TKI-resistant BCR-ABL mutations is a cause of primary and 
secondary treatment failure. In particular T315I is resistant to all available TKI and 
there is concern that selection pressure may result in this mutation becoming more 
prevalent.  The proteasome is an attractive target for cancer therapy and there has 
been expansion of the clinical use of bortezomib, to date the only licensed PI. In 
this study we provide evidence that this drug has potential as a therapy to target 
cells expressing BCR-ABL including T315I mutated forms. There is also evidence 
that the Ph+HSC may be susceptible to the apoptotic effect of this drug. Concerns 
over the relatively non-selective action of bortezomib may potentially be overcome 
by use in combination with TKI. This would be in line with the majority of clinical 
studies of bortezomib where it is now seldom used as monotherapy. 
 
4.2 Targeting BCR-ABL+ cell lines, including mutant forms 
We demonstrate that BCR-ABL+ cell lines (K562 and Ba/F3-p210) are subject to 
reduced  proliferation  and  increased  apoptosis  when  exposed  to  bortezomib  for 
greater than 12h (Figure 3.5). Different techniques were used to establish an LD50   104 
in  K562  and  included  cell  counting  by  vital  dye  exclusion  (LD50  5.6nM  at  48h 
Figure 3.1), cell counting combined with flow cytometry with annexin-V and 7-AAD 
staining (LD50 6nM at 48h Figure 3.2) and 
3H-thymidine proliferation assays (IC50 
8.4 Figure 3.7). Ba/F3 cells transduced and expressing p210 and mutated BCR-
ABL  were  assessed  following  bortezomib  exposure  with  cell  counting  and  flow 
cytometry. An LD50 of between 6.3 and 11.3nM at 24h was established, with no 
significant difference between p210 and the 3 different BCR-ABL mutants (H396P, 
M351T and T315I). These cells were assessed at this early time point as drug 
wash-out experiments indicated that longer exposure was probably not necessary. 
We  confirmed  by  flow  cytometry  for  activated  caspase-3  that  apoptosis  was 
induced  by  bortezomib  in  Ba/F3  cells  (Figure  3.6)  a  result  predicted  by  the 
movement of cell populations through the annexin-V and 7-AAD quadrants with 
continuous drug exposure. 
 
These results may be compared to published work previously demonstrating that 
BCR-ABL+  cell  lines  are  susceptible  to  the  antiproliferative  and  antiapoptotic 
effects of PI. Servida et al. exposed a range of cell lines to the PI bortezomib and 
Z-Ile-Glu(OtBu)-Ala-Leucinal (PSI) – though in this study the LD50 for bortezomib 
in IM-sensitive K562 was 110nM at 48h (by PIo staining and flow cytometry) (8). 
These  results  are  at  variance  with  others  using  flow  cytometry  and  annexin-V 
staining  and  showing  an  LD50  of  32nM  with  bortezomib  in  K562  at  48h  (3).  A 
separate group examined KBM-5 and -7 (as with K562 both lines derived from 
human BC CML) which were either IM sensitive or IM resistant. Assays of cell 
proliferation demonstrated an IC50 between 10-15nM at 48h with identical dose-
response curves between the IM-resistant and sensitive cells lines. This inhibition 
was correlated with accumulation of cells in G2M phase, induction of caspase-3 
and an inhibition of NFkB activity by EMSA (1).  
 
It is difficult to explain why our results with K562 are at variance with Servida et al. 
as a similar technique was adopted. It is unlikely to be due to storage artefact of 
bortezomib  as  we  have  demonstrated  that  freeze-thawing  does  not  appear  to 
enhance the potency of drug effect in the assays used. In addition in all cases the 
bortezomib was obtained directly from the manufacturers. 
 
Our results add evidence to those published previously that IM-resistance does 
not appear to influence bortezomib sensitivity. What is added by our work is that   105 
specific mutations of BCR-ABL are equally sensitive to apoptosis, including the 
T315I mutation. This is clearly of clinical relevance as there is no current licensed 
therapy available for these patients other than conventional treatments such as 
hydroxycarbamide  or  busulphan  which  will  achieve  only  haematological 
responses. Haematopoietic stem cell transplantation is a further option though is 
limited by the toxicity of conditioning regimes – of particular concern in CML which 
is  predominantly  a  disease  of  the  elderly.  The  results  with  bortezomib  can  be 
compared to those generated with the aurora kinase inhibitor MK-0457 (VX680) 
and homoharringtonine (HHT). The aurora kinases are key regulators of mitosis 
and  abnormal  activity  is  associated  with  a  number  of  malignancies  including 
leukaemia.    Aurora  kinase  inhibitors  block  cell-cycle  progression  and  induce 
apoptosis in BCR-ABL+ cell lines, including the T315I mutant (126, 128).  A series 
of 3 patients with the T315I mutation and treated with MK-0457 showed promising 
early  evidence  of  clinical  responses  (127).,  however  clinical  trials  were 
subsequently  stopped  due  to  unacceptable  levels  of  toxicity.  HHT  is  a 
cephalotaxus alkaloid which has previously been shown to have antiproliferative 
effects and induce caspase-3 dependent apoptosis in IM-sensitive and resistant 
BCR-ABL+ cell lines (193). Prior to the introduction of IM, HHT  was used in a 
clinical trial for patients with CP CML with 72% CHR and 15% CCyR achieved 
(194). More recently HHT has been used in 17 patients with IM-resistant CML in 
all  disease  phases.  Conventional  responses  were  obtained  only  in  the  small 
number  of  CP  patients  treated  and  none  were  sustained  (195).  However,  of 
particular interest is emerging data that HHT may have a preferential effect on the 
T315I mutant. This comes from 2 clinical trials where patients with IM-resistant 
CML and the confirmed presence of the T315I mutation have been treated with 
HHT. In both trials a rapid fall in T315I BCR-ABL transcripts was reported with 
associated haematological and cytogenetic responses (99, 196).  
 
In addition we performed baseline proteasome activity assays in the K562  and 
Ba/F3  cells  and  were  surprised  to  document  differences  in  both  PG  and  CT-L 
activity between the Ba/F3 mutants. This reached statistical significance in Ba/F3 
T315I, Ba/F3-H396P and Ba/F3-M351T for CT-L activity  and Ba/F3-H396P and 
Ba/F3-M351T for PG activity. This did not translate into differences in susceptibility 
as shown, though there was a trend for the BCR-ABL mutants to be slightly less 
susceptible.  Multiple  replicates  would  be  required  to  determine  any  subtle 
differences – which may not be of clinical consequence. However such data would   106 
be interesting and comparable to the apparent enhanced susceptibility of T315I 
mutations to HHT (196). Our findings may also augment data published in this field 
comparing the biology of different BCR-ABL mutants, in particular mutations are 
present in IM-naïve patients which may confer a survival advantage to cells (197). 
There are published data demonstrating that BCR-ABL mutants may have differing 
oncogenicity (by transformation of mouse BM cells) and ABL-kinase activity (by 
global  phosphotyrosine  assays)  with  selected  data  demonstrated  in  Table  4.1. 
However, there are no data published comparing the proteasome activity of the 
mutants.  
 
Table 4.1 Published data of BCR-ABL mutants 
BCR-ABL 
mutant 
Transforming 
potential 
Kinase activity  Reference 
T315I  =/↑  ↓  (198, 199) 
H396P  ↓  ↓  (198) 
M351T  ↓  ↓  (199) 
Activity relative to p210 BCR-ABL with ↓ increased and ↑ decreased activity.  
 
With bortezomib treatment we demonstrate the expected inhibition of CT-L activity. 
Data for the Ba/F3 mutants was pooled as little differences were seen between the 
mutants  at  the  concentration  tested  (20nM).  We  also  demonstrated  some 
reduction in PG and T-L activity. This has been demonstrated by others using this 
technique with bortezomib which is reported to be a relatively selective CT-L PI. 
(186).  This  may  reflect  a  limitation  of  the  assay  for  determining  specific 
proteasomal  subunit  activity  or  illustrate  the  theory  that  protein  degredation  is 
reliant  on  all  active  sites  and  so  inhibition  of  CT-L  activity  may  impair  protein 
degradation through other routes (189). We did not assay proteasome activity to 
determine a dose response curve. This has been done previously both in vitro and 
data  has  been  generated  from  clinical  trials.  There  appears  to  be  a  maximally 
tolerated threshold effect at around 80% inhibition where toxicity is significantly 
limiting (177). This may reflect the non-selective nature of proteasome inhibition 
and there may be an exposure level at which all cells will be unable to function and 
so  undergo  apoptosis.  It  is  reassuring  to  see  that  the  concentration  used  here 
(20nM)  generated  significant  apoptosis  in  Ba/F3  cells  however  was  associated 
with only approximately 40% inhibition of substrate release. This may also indicate 
that  bortezomib may  have targets other than the  proteasome. Though  not fully   107 
characterised it has been demonstrated that bortezomib targets non-proteasomal 
cellular  enzymes  including  the  protease  enzymes  cathepsin  A/G  and  chymase 
(200).  
 
It  has  previously  been  shown  by  using  FDCP-MIX  cells  transfected  with  a 
temperature sensitive BCR-ABL construct that BCR-ABL activity is associated with 
an increase in proteasome activity, as measure by release of fluorescent AMC-
bound peptides. The BCR-ABL+ cells were also more susceptible than BCR-ABL- 
cells to apoptosis induced by PI (BzL-LLCOCHO) exposure (2). No clear pathway 
has been established linking the proteasome to BCR-ABL activity. However BCR-
ABL activity has been associated with constitutive NFkB activity, reduced levels of 
CDKi and an altered balance  of pro and  antiapoptotic mediators – all of which 
involve  potential  proteasomal  substrates.  It  is  possible  that  the  proteasome  is 
activated by one or a number of the many molecular pathways activated by BCR-
ABL kinase. We were interested to note that in K562 exposure to bortezomib for 
48h  was  associated  with  a  reduction  in  pCrkl  in  a  dose-dependent  manner, 
consistent with reduced BCR-ABL activity. This is consistent with results published 
by  Soligo  et  al.  where  reduced  BCR-ABL  protein  was  detected  at  48h  with 
exposure of K562 to PSI (201). These results contrast with Yan et al. who failed to 
detect  any  difference  in  BCR-ABL  protein  in  K562  with  48h  exposure  to  32nM 
bortezomib.  We  did  not  probe  for  BCR-ABL  protein  levels  and  so  direct 
comparisons  cannot  be  drawn.  It  is  conceivable  that  the  proteasome  may  be 
influencing stability and/or activity of proteins downstream of BCR-ABL modulating 
phosphorylation  of  Crkl  though  further  characterisation  of  this  was  considered 
beyond the scope of this project. 
 
4.3 Targeting the CML stem cell 
We have demonstrated that CD34+ selected leukapheresis samples taken from 
patients  with  CP  CML  at  diagnosis  are  susceptible  to  the  antiproliferative  and 
apoptotic effects of bortezomib. CML CD34+ cells were  exposed to bortezomib 
and  cultured  in  SFM+5GF.  The  LD50  was  8.8±0.7nM  (n=5)  at  24h,  7.6±0.4nM 
(n=3) at 48h and 5.7±1.6nM (n=7) at 72h. The different patient samples selected 
did  not  appear to vary in  susceptibility to this drug and the absence of  growth 
factors  did  not  significantly  affect  responses.  The  expansion  of  CML  CD34+  in 
SFM+5GF  was  impaired  in  the  presence  of  the  drug  indicating  an  additional 
antiproliferative effect. These results are illustrated in Figures 3.12A-C. Evidence   108 
for  apoptosis  was  provided  by  the  increase  in  detectable  intracellular  activated 
caspase-3 with bortezomib exposure (detected by flow cytometry, Figure 3.13B) 
and  the  cleavage  of  PARP  (detected  by  Western  blotting,  Figure  3.14).  The 
concentration  of  bortezomib  required  to  achieve  these  results  is  similar  to  that 
inhibiting proliferation of human multiple myeloma cells (IC50 2.5-30nM (5)) and 
CD34+ selected human AML samples (IC50 5-10nM at 7d (6)). 
 
We  utilised  Western  blotting  to  detect  the  accumulation  of  polyubiquitinated 
proteins as a marker of proteasome inhibition. This was clearly demonstrated in 
CML CD34+ following 24h exposure to bortezomib though not with TKI therapy 
(Figure 3.15A and 3.16). This time point was chosen for consistency of analysis 
allowing correlation with experiments assessing apoptosis and proliferation – in 
turn  based  on  drug  wash-out  experiments  in  cell  lines.  There  is  published 
evidence  that  a  much  shorter  exposure  of  1h  is  required  to  achieve  maximum 
proteasomal inhibition in vivo (168) though the recovery of cells in vitro following 
short exposure may relate to the reversible inhibition associated with bortezomib.  
 
We also demonstrate effects on the CDKi p57
kip2 (Figure 3.16). This is consistent 
with  an  inhibitory  effect  of  PI  on  cell  cycling  through  the  prevention  of  the 
enhanced removal of CDKi seen in a number of malignancies including CML. PI 
treatment of CML has been associated with increased levels of p27
kip1 and p21
cip1 
which are both members of the CIP/KIP family which also includes p57
kip2 (145, 
147, 148). This is of particular interest as it has been shown that p57
kip2 but not 
p27
kip1 sensitises cancer cells to apoptosis by mitochondrial translocation resulting 
in loss of MMP and release of cytochrome c with consequent apoptosis (202).  
 
In contrast to the results shown for the K562 cell line, we did not demonstrate 
significant effects on BCR-ABL activity with up to 20nM bortezomib exposure for 
up to 48h. There are a number of potential explanations for these differences. The 
comparison  is  between  an  immortalised  BC  cell  line  and  a  CP  patient  derived 
CD34+ selected product and so there is likely to be inherent differences in the 
balance of intracellular signalling pathways between these samples. It may be that 
longer exposure or higher concentrations of bortezomib are required to achieve 
the effect on BCR-ABL activity seen in K562. However we were interested to note 
significant  BCR-ABL  activity  was  detected  in  CD34+  CML  samples  at 
concentrations in excess of the LD50 and the derived area-under-the-curve drug   109 
exposure in vivo. This would be consistent with the proteasome functioning either 
independently of BCR-ABL or downstream through activated signalling pathways. 
However there are caveats to both of these suggestions – BCR-ABL activity in cell 
lines is associated with increased proteasome activity and effective TKI exposure 
does  not  result  in  accumulation  of  polyubiquitinated  proteins  as  detected  by 
Western blot. It may be that BCR-ABL does mediate an increase in proteasome 
activity  beyond  basal  levels.  TKI  therapy  may  ameliorate  though  not  obliterate 
proteasome  function  which  may  continue  at  a  sufficient  rate  to  clear 
polyubiquitinated  proteins.  It  is  also  speculated  that  the  accumulation  of 
ubiquitinated proteins may be minimised by stimulation of autophagy – a process 
related to proteasomal function which will be discussed. There may be additional 
interactions  between  BCR-ABL  and  the  proteasome  illustrated  by  work 
investigating molecular chaperones.  It has  been shown  in BCR-ABL+ cell lines 
that  BCR-ABL  depends  on  an  association  with  HSP90  to  maintain  stability. 
Targeting this association with HSP90 inhibitors (including geldanamycin and 17-
AAG) results in increased ubiquitination and proteasomal degradation of BCR-ABL 
(p210 and mutated forms) (107, 109, 110). Proteasome inhibition may therefore 
protect cells against BCR-ABL breakdown. 
 
We next used FACS to isolate the CD34+38- fraction from 3 CD34+ CML patient 
samples. It is within this population that primitive progenitor cells are enriched with 
evidence for this shown in Table 1.1. The LD50 at 24h was 8.93±1.42nM. This was 
similar to that of unsorted CML CD34+ cells and no significant difference was seen 
when  comparing  relatively  primitive  CD34+38-  cells  to  more  mature  and 
proliferative CD34+38+ (Figure 3.17B).  
 
To further assess the effect of bortezomib exposure on the different populations of 
cells we cultured CML CD34+ cells for 72h with CFSE. This provided insight into 
the number of divisions cell populations had undergone in different experimental 
conditions.  As  demonstrated  previously  dasatinib  exposure  was  antiproliferative 
(Figure 3.19 and (4)). Bortezomib treatment at concentrations >5nM showed a 
more marked effect and with 20nM exposure, of the remaining few cells surviving, 
the majority had failed to divide with the curve overlying that of the Colcemid® 
control.  Furthermore  as  the  cells  divided  in  the  presence  of  bortezomib  they 
appeared  to  maintain  a  less  mature  phenotype  as  evident  in  the  retention  of 
CD34+  surface  staining.  This  phenomenon  has  been  noted  by  others  culturing   110 
CD34+ CML cells in the absence of exogenous growth factors and may reflect the 
reduced proliferative potential of cells exposed to bortezomib and it is speculated 
that this may reflect a tendency to undergo self-renewal divisions (60).  
 
To  determine  the  numbers  of  CD34+  viable  cells  for  each  division  peak  we 
performed recovery calculations based on the assumption that cells will divide in a 
balanced  manner  with  1  cell  producing  2  progeny  with  equal  potential  for 
replication. We analysed cells exposed to 10nM bortezomib as this was close to 
the  LD50  though  it  is  accepted  that  the  sustained  drug  exposure  potentially 
achieved in vivo for this time period with conventional drug dosing is not known. 
We discovered differences between the 3 samples analysed in this way, however 
when assessing recovery from all division peaks with both dasatinib 150nM and 
bortezomib  10nM  exposure  there  was  impaired  recovery  of  CD34+  cells  – 
consistent with loss of cells presumably through apoptosis. When the undivided 
peak  was  assessed  the  differences  were  more  marked,  though  only  small 
numbers  of  cells  contributed  to  these  peaks.  Here  it  was  seen  in  2  of  the  3 
samples  examined  there  was  an  increase  in  recovery  of  undivided  (quiescent) 
CD34+ cells with dasatinib (consistent with published data (4)) in contrast to a 
reduction in this cell population with bortezomib 10nM. This is significant as the 
quiescent  Ph+CML  is  thought  to  contribute  to  MRD  in  TKI  treated  CML. 
Bortezomib  appears  to  have  the  potential  to  reduce  this  population  at 
concentrations which may be clinically relevant as demonstrated in an effect on 
FACS sorted CD34+38- cells and from the CFSE data in which cell division was 
tracked. However the cells are not eradicated and the concentration of bortezomib 
may be critical as higher levels appear to be ineffective in targeting the undivided 
cells and retention of CD34+ staining may reflect a stimulus to self-renewal and so 
maintenance of MRD.  
 
4.4 Relative non-selectivity of bortezomib 
The proteasome is found in all eukaryotic cells and plays a vital role in cellular 
functions – including those resulting in proliferation and apoptosis. Inhibition of the 
proteasome is therefore inherently a non-selective strategy to target cancer cells 
and relies on exploiting a difference in proteasome activity levels, a dependence 
on that activity and/or the ability to recover from disruption to protein turnover. We 
analysed 2 FACS sorted CD34+38- non-CML samples and demonstrated that at 
24h drug exposure the LD50  was 10.18±1.85nM - not significantly different to the   111 
results  obtained  for  a  similar  population  of  CP  CML  cells  (Figure  3.17C).  To 
establish any true difference between CML and normal would clearly require more 
replicates,  however  a  limited  number  of  non-CML  samples  were  available  for 
analysis in our laboratory. It is interesting to note of the little published in this field 
there is marked variation in results obtained (Table 4.2). The variation may reflect 
a  difference  in  techniques  applied,  time-points  of  analysis  and  cells  used  as 
representative  of  “normal”  controls.  There  is  no  published  data  assessing  the 
effects of bortezomib on the CD34+38- sorted population as shown here. However 
Servida et al have assessed the effects of a different PI on normal primitive HSC. 
They  performed  LT-CIC  assays  with  3  normal  BM  samples  at  a  single 
concentration of PSI chosen as equivalent to the IC50 demonstrated in CML by 
CFU-GM  assay. This concentration  did not influence colony formation and was 
therefore considered selective for CML (8).  
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Table 4.2 Published effect of bortezomib on normal cells 
Cells  Technique  IC50/LD50  Timepoint  Reference 
PB MNC  Thymidine 
incorporation 
>100nM  48h  (5) 
  Annexin-V 
staining 
50nM  induced 
48±22% 
apoptosis 
48h  (9) 
CD34+ BM  Annexin-V 
staining 
50nM  induced 
5±5.2% 
apoptosis 
18h  (9) 
  CFU-GM  11.3nM  14d  (8) 
  Thymidine 
incorporation 
<20nM  7d  (6) 
  MTT  260-780nM  48h  (203) 
The technique applied and the timepoint for analysis is obtained from the relevant 
publication  and  the  IC50  or  LD50  quoted  where  available.  Colony  forming  units 
granulocyte-macrophage  (CFU-GM),  MTT  assay  is  a  conventional  proliferation 
assay  measuring  a  colour  change  of  3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium  bromide  (MTT)  by  mitochondrial  activity,  Peripheral  blood 
mononuclear  cells  (PB  MNC)  and  CD34+  selected  bone  marrow  cells  (CD34+ 
BM). 
 
4.5 Combination of bortezomib with dasatinib 
Drug  combinations  are  commonly  utilised  for  cancer  therapy  and  provide  a 
mechanism  for  enhancing  the  effect  of  an  agent  without  increased  toxicity. 
Bortezomib is now commonly used in combination with other therapies in clinical 
trials  and  this  is  perhaps  not  a  surprise  when  the  myriad  cellular  processes 
potentially  affected  by  this  drug  are  considered.  Bortezomib  combinations  also 
offer a mechanism to minimise the significant toxicity associated with this drug. In 
the  APEX  trial  published  in  2005  where  patients  were  treated  with  the  now 
established 1.3mg/m2 on days 1, 4, 8 and 11 in 3-week cycles, 37% discontinued 
treatment as a consequence of side-effects. Most common serious events (grade 
3 or  4 by NCI  common toxicity  criteria)  were thrombocytopaenia, anaemia  and 
neutropaenia.  Other  more  common  toxicities  included  gastrointestinal  upset 
(diarrhoea, nausea and vomiting in 57%, 57% and 35% of patients respectively) 
and peripheral neuropathy (in 36% of patients).  
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We  combined  bortezomib  with  dasatinib.  Dasatinib  was  selected  as  the  most 
potent TKI available in the clinic and therefore would enable maximal inhibition of 
BCR-ABL activity in combination with potent proteasomal inhibition by bortezomib. 
We did not investigate the molecular pathways which may link BCR-ABL activity 
and the proteasome, though we provide evidence that PI does not affect BCR-ABL 
activity  and  TKI  does  not  significantly  affect  proteasome  activity  as  evident  by 
accumulation of polyubiquitinated proteins. It has been demonstrated previously 
by  analysis  of  RNA  transcripts  that  primitive  Ph+HSC  (CD34+38-)  express 
relatively higher levels of BCR-ABL than more mature CML cells (4). These cells 
may have relatively higher proteasome activity if the association demonstrated in 
cell lines holds true (2). We hypothesised therefore that the proteasome and BCR-
ABL  may  provide  2  targets  and  concomitant  inhibiton  of  these  would  be 
synergistic. Our results in CD34+ cells are consistent with this demonstrating slight 
synergism  to  synergism  seen  at  fixed  ratio  combinations  of  dasatinib  and 
bortezomib  at  clinically  relevant  concentrations  (Table  3.3). We did  not  assess 
CD34+38- cells or non-CML cells in this way.  
 
Other groups have assessed TKI in combination with PI in CML cells. Gatto et al.  
exposed  BC  CML  cell  lines  to  IM  and  bortezomib  simultaneously  at  a  single 
concentration  of  bortezomib  (11nM)  and  failed  to  demonstrate  synergy  (1). 
Aichberger et al. combined either IM or nilotinib with MG132 in BCR-ABL+ cell 
lines (including K562 and Ba/F3 cells) and assessed by 
3H-thymidine incorporation 
for cell proliferation. No data was presented in the paper though it was stated that 
no synergy was seen (155). We are the first to present data where dasatinib has 
been combined with bortezomib in CD34+ CML samples. Different factors may 
contribute to the more positive data generated in this project: dasatinib would be 
expected to induce more potent BCR-ABL inhibition than IM or nilotinib; and we 
assessed untreated CP CML CD34+ samples in contrast to the BC CML cell lines 
and transduced murine cells used by other groups.  
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4.6 Potential future work 
There is scope to extend the work produced by this project from cell line, patient 
samples and stem cell data. 
 
4.6.1 Extension of cell line data 
We  provided  evidence  that  BCR-ABL+  cell  lines  have  detectable  proteasome 
activity  and  furthermore  this  activity  may  vary  between  BCR-ABL  mutations.  It 
would be important to establish whether this translates to a subtle difference in 
susceptibility to the apoptotic and antiproliferative effects and levels of detectable 
proteasome  activity.  This  could  be  assessed  with  a  series  of  dose-response 
experiments using bortezomib and the 4 BCR-ABL+ Ba/F3 mutants. Confirmed 
differences would imply a biological difference between the cell lines in line with 
current work in this field. 
 
4.6.2 Extension of patient sample data 
All CD34+ samples were taken at diagnosis from patients with CP CML. It would 
be of relevance clinically to establish whether BCR-ABL+ cells taken from patients 
who  have  failed  IM  therapy  due  to  IM-resistance  of  intolerance  demonstrate 
comparable sensitivity. Such cell samples are available through a collaborator (F. 
Niccolini) and testing of these forms the basis of a future project.  
 
4.6.3 Extension of stem cell data 
We did not perform functional analysis of the CD34+ CML cells to characterise the 
influence of bortezomib on the ability of cells to form colonies or to persist in long 
term culture. To confirm an effect on the most primitive quiescent population of 
Ph+HSC It is important to establish whether bortezomib (as monotherapy or in 
combination with TKI) influences LTC-IC potential. This could be performed as a 
4-arm  experiment  comparing  untreated  CD34+  CML  cells  with  dasatinib  and 
bortezomib  alone  or  in  combination.  Such  an  experiment  would  also  yield 
additional CFU data, a further measure of proliferation and differentiation. A logical 
extension  to  LTC-IC  would  involve  transplantation  of  treated  and  untreated 
Ph+HSC  into  immune  compromised  mice.  Such  work  has  been  performed  by 
Guzman et al. where normal (cord blood) and AML CD34+38- cells were treated 
with  a  combination  of  idarubicin  and  MG132  prior  to  transplantation  into 
NOD/SCID  mice.  Engraftment  was  significantly  impaired  in  the  treated  AML   115 
population  when  compared  to  control  indicating  a  selective  effect  of  this 
combination on the disease HSC (7).  
 
Functional  HSC  assays  may  also  characterise  any  affect  of  bortezomib  on  the 
promyelocytic leukaemia (PML) gene. PML is a tumour suppressor that controls 
apoptosis,  proliferation,  senescence  and  is  involved  in  neoangiogenesis.  It  is 
highly expressed in the normal human HSC and is required for HSC maintenance. 
In  Ph+HSC  PML  is  highly  expressed  and  through  experiments  by  which  PML 
knockdown cells were transduced with BCR-ABL it is seen that PML is required for 
maintenance  of  LTC-IC.  Furthermore  downregulation  of  PML  is  effective  for 
eradication  of  leukaemia  initiating  cells  (204).  PML  is  a  target  for  proteasomal 
breakdown and PI exposure (MG132) of cell lines (HEK) increases PML levels 
(205).  It  may  be  speculated  that  the  effect  of  bortezomib  on  the  primitive 
population may involve an effect on PML. 
 
4.6.4 Future clinical trials 
The data generated from this project has potential clinical translation. As a front-
line  therapy  bortezomib  use  may  be  difficult  to  support.  IM  is  an  effective  well 
tolerated  oral  drug  with  7y  of  clinical  trial  data  supporting  its  use.  Bortezomib 
would be a clinically unproven, is only available as an intra-venous infusion and 
though relatively well tolerated, has potential toxicities which may be considered 
unacceptable  when  compared  to  IM.  It  is  likely  that  an  appropriate  role  for 
bortezomib would be for those resistant to or intolerant of current treatment, or as 
a  combination  therapy  with  TKI.  We  have  generated  data  that  suggests  that 
bortezomib targets the primitive Ph+HSC population and so would be expected in 
vivo to reduce MRD to undetectable levels – though clearly in vivo supportive data 
would be required prior to use in patients, for example through transplantation of 
NOD/SCID  mice  with  treated  cells.  The  combination  data  of  dasatinib  and 
bortezomib  are  of  particular  interest.  These  drugs  used  together  as  front-line 
therapy  may enable  a significant and rapid  reduction  of disease  burden  with  a 
presumed associated improved outcome – as shown for those in the IRIS trial who 
had a relatively rapid response to IM. An alternative strategy would be to pursue 
the use of bortezomib in those  with TKI-resistance, in particular those  with the 
T315I  mutation.  A  combination  of  bortezomib  and  dasatinib  in  this  group  may 
enable control of T315I and prevent selection for other TKI-sensitive mutations. 
New  PI  are  under  development  with  successful  application  in  clinical  trials   116 
involving  patients  with  mantle  cell  lymphoma  or  multiple  myeloma.  Of  these 
Carfilzomib is of particular interest as it is reported to have similar CT-L inhibitory 
activity  to  bortezomib,  though  with  fewer  “off-target”  effects  and  so  reduced 
unwanted toxicity (200). It would therefore be of particular interest to assess this 
drug in vitro as bortezomib has been assessed here.    117 
5 CONCLUSIONS 
 
CML  is  treated  effectively  with  TKI,  however  two  key  problems  remain  -  the 
insensitivity  of  CM  HSC  to  TKI  and  the  emergence  of  TKI-resistant  BCR-ABL 
mutations. BCR-ABL activity is associated with increased proteasome activity and 
PI  are  cytotoxic  against  CML  cell  lines.  We  demonstrate  that  bortezomib  is 
antiproliferative  and  induces  apoptosis  in  CD34+  cells  taken  at  diagnosis  from 
patients with CP CML cells, with an LD50 below concentrations achieved in vivo. 
We also demonstrate for the first time that CD34+38- CML cells, representing the 
TKI-insensitive primitive HSC, are similarly susceptible. Bortezomib is associated 
with  inhibition  of  proteasome  activity,  however  that  of  BCR-ABL  appears 
unaffected. Significant synergy is seen when bortezomib and dasatinib are used in 
combination.  We  also  demonstrate  that  bortezomib  is  effective  in  inhibiting 
proteasome  activity  and  inducing  apoptosis  in  cell  lines  expressing  BCR-ABL 
mutations, including T315I. Therefore we believe that bortezomib offers a potential 
therapeutic option in CML by targeting both TKI-insensitive stem cells and TKI-
resistant BCR-ABL mutations. 
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